



US007718697B2

(12) **United States Patent**
Drace et al.(10) **Patent No.:** US 7,718,697 B2
(45) **Date of Patent:** May 18, 2010(54) **METHOD FOR TREATING GLAUCOMA
COMPRISING ADMINISTERING α -LIPOIC
ACID**(75) Inventors: **Colene D. Drace**, Fort Worth, TX (US);
Gary W. Williams, Burleson, TX (US);
Curtis R. Kelly, Arlington, TX (US);
Najam A. Sharif, Keller, TX (US)(73) Assignee: **Alcon, Inc.**, Hunenberg (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 1280 days.

(21) Appl. No.: **11/006,007**(22) Filed: **Dec. 7, 2004**(65) **Prior Publication Data**

US 2005/0137123 A1 Jun. 23, 2005

Related U.S. Application Data

(60) Provisional application No. 60/530,436, filed on Dec. 17, 2003.

(51) **Int. Cl.**
A61K 31/19 (2006.01)(52) **U.S. Cl.** **514/557**(58) **Field of Classification Search** None
See application file for complete search history.(56) **References Cited**

U.S. PATENT DOCUMENTS

- 5,145,871 A * 9/1992 Cavazza 514/546
5,288,735 A * 2/1994 Trager et al. 514/363
5,364,884 A * 11/1994 Varma et al. 514/551
2002/0102581 A1 8/2002 Hageman et al.
2004/0104646 A1 6/2004 Kelly et al.

FOREIGN PATENT DOCUMENTS

WO WO02/20028 * 3/2002

OTHER PUBLICATIONS

- Gutteridge, Clinical and Exp. Optometry, vol. 83, 161-172, 2000.*
Filina et al., Vestn. Oftalmol. 1995 as printed by the Examiner from [www.ncbi.nlm.gov/pubmed]. pubmed# 8604540 obtained on Apr. 16, 2009, p. 1-2.*
Filina et al English Trnaslation: An English translation of Felina et al. Vestn. Oftalmol. 1995 by USPTO-STIC (PTO-09-4740), pp. 1-11.*
Lipoic acid: Medical Subject Headings printed by the Examiner from [www.nlm.nih.gov/cgi/mesh/2009] on Apr. 16, 2009, pp. 1-3.*
Abler, et al., Commun. Mol. Path. & Pharm. 92:177-189 (1996).
Ambati, J., et al., Surv. Ophthalmol. 48:257-293 (2003).
Asrani and Zeimer, Br. J. Ophthalmol. 79(8):776-780 (1995).
Asrani, et al., Inv. Ophthalmol. Vis. Sci. 38(13):2702-2710 (1997).
Bengtsson, Br J Ophthalmol, vol. 73, pp. 483-487 (1989).
Bressler, et al., Sur. Ophthalmol, 32:375-413 (1988).
Brown, M., Drug Discov. Today 8:474-475 (2003).
Burns and Duff, Neurochem Res. 28:979-986 (2003).
Caricasole, A., et al., Trends Pharmacol. Sci. 24:233-238 (2003).
Chabry, J., et al., J. Neurosci. 23:462-469 (2003).
Chang, B-D., et al., Proc. Nat. Acad. Sci., USA 97:4291-4296 (2000).
Ciulla, et al., Sur. Ophthalmol. 43:134-146 (1988).

- Curcio, et al., Inv. Ophthalmol. Vis. Sci. 37:1236-1249 (1996).
Damiens et al., Oncogene, 20(29):3786-3797 (2001).
Eldar-Finkelman, H., Trends Mol. Med. 8:126-132 (2002).
Ermilov et al., Arkh Patol, "Senile amyloidosis of the eye as a manifestation of senile cerebral amyloidosis", 43-45 (Russian) (1993).
Fakforovich, et al., Nature 347:83-86 (1990).
Frankiewicz and Parsons, Neuropharmacol. 38:1253-1259 (1999).
Ge-Zhi, et al., Trans. Am. Ophthalmol. Soc. 94:411-430 (1996).
Gragoudas, et al., Inv. Ophthalmol. Vis. Sci. 38(4)S17 (1997).
Gupta-Bansal and Brunden, J. Neurochem. 70:292-298 (1998).
Hock, C., et al., Amyloid: J. Prot. Fold. Disord. 10:1-6 (2003).
Husain, et al., Ophthalmol. 104(8):1242-1250 (1997).
Janus, C., et al., Nature 408:979-982 (2000).
Jen, LS., et al., Nature 392:140-141 (1998).
Jensen, LE and Whitehead, AS, Biochem. J. 334:489-503 (1998).
Johan, K., et al., Proc. Nat. Acad. Sci. USA 95:2558-2563 (1998).
Kane, M.D., et al., J. Neurochem. 72:1939-1949 (1999).
Kindy, M.D., et al., J. Alzheimer's Disease 1:155-167 (1999).
Koriyama, Y., et al., Eur. J. Pharmacol. 458:235-241 (2003).
Krasnov, Vestn Oftalmol, "Morphological features of senile and secondary amyloidosis of the iris and sclera in patients with glaucoma" abstract (Jan.-Mar. 1996).
Kumon, Y., et al., Scand. J. Immunol. 53:7-12 (2001).
Kumon, Y., et al., Amyloid 9:237-241 (2002).
Kumon, Y., et al., Scand. J. Immunol. 56:504-511 (2002).
Lambert, M.P., et al., Proc. Nat. Acad. Sci. USA 95:6448-6453 (1998).
Lanz, T.A., et al., J. Pharmacol. Expt. Ther. 305:864-871 (2003).
LaVail, et al., Proc. Nat. Acad. Sci. 89:11249-11253 (1992).
Leske, M.C., et al., American Journal of Epidemiology, 118(2):166-191 (Aug. 1983).
Liang, J.S., et al., Neurosci. Lett. 225:73-76 (1997).
Lin, et al., Curr. Eye Res. 13(7):513-522 (1994).
Liu, Y., et al., J. Neurochem. 69:2285-2293 (1997).
Marks, N. and Berg, M.J., Neurochem. Res. 28:1049-1062 (2003).
Matsuoka, Y., et al., J. Neurosci. 23:29-33 (2003).
Miida, T., et al., Biochem. 38(51):16958-16962 (1999).
Morgan, D., et al., Nature 408:982-985 (2000).
Naash, et al., Inv. Ophthalmol. Vis. Sci. 37:775-782 (1996).
Nakagami, Y. and Oda, T., Jpn. J. Pharmacol. 88:223-226 (2002).
Nakagami, Y., et al., Br. J. Pharmacol. 137:676-682 (2002).
Nakagami et al., Eur J P, 457:11-17 (2002).
Noell, et al., Invest. Ophthalmol. Vis. Sci. 5:450-472 (1966).
O'Hara, R., et al., Arthritis Res. 2:142 (2000).
Pike, C.J., et al., J. Neurosci. 13:1676-1687 (1993).
Schenk, D., et al., Nature 400:173-177 (1999).
Schwartz et al., Ophthalmology, 89(4):394-401 (1982).
Sickenberg, et al., Inv. Ophthalmol. Vis. Sci. 38(4):S92 (1997).

(Continued)

Primary Examiner—Robert Landsman**Assistant Examiner**—Gyan Chandra(74) **Attorney, Agent, or Firm**—Teresa J. Schultz(57) **ABSTRACT**

The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21^{Waf1/Cip1/Sd1} genes to treat such disorders of the eye.

1 Claim, No Drawings

OTHER PUBLICATIONS

Strong, N. P., "How optometrists screen for glaucoma: A survey", Ophthal. Physiol. Opt., 12:3-7 (1992).
Taylor, et al., Arch. Ophthalmol. 110:99-104 (1992).
Thomas, et al., Inv. Ophthalmol. Vis. Sci. 39(4):S242 (1998).
Thorn, C.F., et al., J. Immunol. 169:399-406 (2002).
Uhlar, C.M., et al., Eur. J. Biochem. 265:501-523 (1999).
Urieli-Shoval, S., et al., J. Histochem. Cytochem. 46:1377-1384 (1998).
Vaughan, D. et al., In: General Ophthalmology, Appleton & Lange, Norwalk, Conn., pp. 213-230 (1992).

Walder, et al., Diabetes 51:1859-1866 (2002).
Xia, W., Drug News Perspect. 16:69-73 (2003).
Xiang et al., (2002) Neurobiol. Aging 23:327-334.
Yamada, et al., Scand. J. Immunol. 52:7-12 (2000).
Yamazaki, et al., Biochemical and Biophysical Res. Comm. 290:1114-1122 (2002).
Yankner et al., Science, 250:279-282 (1990).
Young, Sur. Ophthalmol. 32:252-269 (1988).
Zhang, L., et al., Neurosci. Lett. 312:125-128 (2001).

* cited by examiner

1

**METHOD FOR TREATING GLAUCOMA
COMPRISING ADMINISTERING α -LIPOIC
ACID**

This application claims priority from the provisional application, U.S. Patent Application Ser. No. 60/530,436 filed Dec. 17, 2003.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to the field of diagnosis and treatment of glaucoma. More specifically, the invention provides methods and compositions for treating ocular hypertension, glaucoma and age-related macular degeneration (ARMD) and for identifying therapeutic agents to treat these blinding diseases.

2. Description of the Related Art

There are a number of ocular conditions that are caused by, or aggravated by, damage to the optic nerve head, degeneration of ocular tissues, and/or elevated intraocular pressure. For example, "glaucomas" are a group of debilitating eye diseases that are a leading cause of irreversible blindness in the United States and other developed nations. Primary Open Angle Glaucoma ("POAG") is the most common form of glaucoma. The disease is characterized by the degeneration of the trabecular meshwork, leading to obstruction of the normal ability of aqueous humor to leave the eye without closure of the space (e.g., the "angle") between the iris and cornea (Vaughan, D. et al., (1992)). A characteristic of such obstruction in this disease is an increased intraocular pressure ("IOP"), resulting in progressive visual loss and blindness if not treated appropriately and in a timely fashion. The disease is estimated to affect between 0.4% and 3.3% of all adults over 40 years old (Leske, M. C. et al. (1986); Bengtsson, B. (1989); Strong, N. P. (1992)). Moreover, the prevalence of the disease rises with age to over 6% of those 75 years or older (Strong, N. P., (1992)).

Glaucoma affects three separate tissues in the eye. The elevated IOP associated with POAG is due to morphological and biochemical changes in the trabecular meshwork (TM), a tissue located at the angle between the cornea and iris. Most of the nutritive aqueous humor exits the anterior segment of the eye through the TM. The progressive loss of TM cells and the build-up of extracellular debris in the TM of glaucomatous eyes leads to increased resistance to aqueous outflow, thereby raising IOP. Elevated IOP, as well as other factors such as ischemia, cause degenerative changes in the optic nerve head (ONH) leading to progressive "cupping" of the ONH and loss of retinal ganglion cells and axons. The detailed molecular mechanisms responsible for glaucomatous damage to the TM, ONH, and the retinal ganglion cells are unknown.

Twenty years ago, the interplay of ocular hypertension, ischemia and mechanical distortion of the optic nerve head were heavily debated as the major factors causing progression of visual field loss in glaucoma. Since then, other factors including excitotoxicity, nitric oxide, absence of vital neurotrophic factors, abnormal glial/neuronal interplay and genetics have been implicated in the degenerative disease process. The consideration of molecular genetics deserves some discussion insofar as it may ultimately define the mechanism of cell death, and provide for discrimination of the various forms of glaucoma. Within the past 8 years, over 15 different glaucoma genes have been mapped and 7 glaucoma genes identified. This includes six mapped genes (GLC1A-GLC1F) and two identified genes (MYOC and

2

OPTN) for primary open angle glaucoma, two mapped genes (GLC3A-GLC3B) and one identified gene for congenital glaucoma (CYP1B1), two mapped genes for pigmentary dispersion/pigmentary glaucoma, and a number of genes for developmental or syndromic forms of glaucoma (FOXC1, PITX2, LMX1B, PAX6).

Thus, each form of glaucoma may have a unique pathology and accordingly a different therapeutic approach to the management of the disease may be required. For example, a drug that effects the expression of enzymes that degrade the extracellular matrix of the optic nerve head would not likely prevent RGC death caused by excitotoxicity or neurotrophic factor deficit. In glaucoma, RGC death occurs by a process called apoptosis (programmed cell death). It has been speculated that different types of insults that can cause death may do so by converging on a few common pathways. Targeting downstream at a common pathway is a strategy that may broaden the utility of a drug and increase the probability that it may have utility in the management of different forms of the disease. However, drugs that effect multiple metabolic pathways are more likely to produce undesirable side-effects. With the advent of gene-based diagnostic kits to identify specific forms of glaucoma, selective neuroprotective agents can be tested with the aim of reducing the degree of variation about the measured response.

Glaucoma is currently diagnosed based on specific signs of the disease (characteristic optic nerve head changes and visual field loss). However, over half of the population with glaucoma are unaware they have this blinding disease and by the time they are diagnosed, they already have irreversibly lost approximately 30-50% of their retinal ganglion cells. Thus, improved methods for early diagnosis of glaucoma are needed.

Current glaucoma therapy is directed to lowering IOP, a major risk factor for the development and progression of glaucoma. However, none of the current IOP lowering therapies actually intervenes in the glaucomatous disease process responsible for elevated IOP and progressive damage to the anterior segment continues. This is one possible reason why most patients become "resistant" to conventional glaucoma therapies. Thus, what is needed is a therapeutic method for altering (by inhibiting or even reversing) the disease process.

Another blinding disease is age-related macular degeneration (ARMD) that affects the outer retina, retinal pigmented epithelial cells, Bruch's membrane, and the choroid. (Ambati et al. 2003). The hallmarks of this disease are diffuse and focal thickening of the Bruch's membrane due to deposition of lipoproteins (drusen) leading to retinal dysfunction culminating in retinal detachment and loss of vision. Other lipoproteins, such as Tanis gene receptor and SAA, may also be deposited at the Bruch's membrane to exacerbate the pathology and retinal dysfunction.

There are several reports suggesting that primary amyloidosis may be associated with glaucoma. For example, it was found that amyloid was deposited in various ocular tissues including the vitreous, retina, choroid, iris, lens, and trabecular meshwork in primary systemic amyloidosis patients (Schwartz et al. 1982). Ermilov et al. (1993) reported that in 478 eyes of 313 patients (aged 25 years to 90 years) with cataracts, glaucoma, and/or diabetes mellitus, 66 (14%) of the eyes contained amyloid-pseudoexfoliative amyloid (PEA) proteins. Krasnov et al. (1996) reported that 44.4% of 115 patients with open-angle glaucoma revealed extracellular depositions of amyloid proteins. Finally, amyloidosis was revealed in the sclera in 82% of the cases and in the iris in 70% of the cases. A number of clinical conditions, including Alzheimer's disease, exhibit abnormal amyloid deposits in

tissues associated with the disease. However, amyloids are molecularly heterogeneous and encoded by different amyloid genes. The previous reports are unclear regarding which amyloid(s) might be associated with glaucoma.

To date, more than 100 genes have been mapped or cloned that may be associated with retinal degeneration. The pathogenesis of retinal degenerative diseases such as age-related macular degeneration (ARMD) and retinitis pigmentosa (RP) is multifaceted and can be triggered by environmental factors in those who are genetically predisposed. One such environmental factor, light exposure, has been identified as a contributing factor to the progression of retinal degenerative disorders such as ARMD (Young 1988). Photo-oxidative stress leading to light damage to retinal cells has been shown to be a useful model for studying retinal degenerative diseases for the following reasons: damage is primarily to the photoreceptors and retinal pigment epithelium (RPE) of the outer retina (Noell et al. 1966; Bressler et al. 1988; Curcio et al. 1996); they share a common mechanism of cell death, apoptosis (Ge-Zhi, et al. 1996; Abler et al. 1996); light has been implicated as an environmental risk factor for progression of ARMD and RP (Taylor et al. 1992; Naash et al. 1996); and therapeutic interventions which inhibit photo-oxidative injury have also been shown to be effective in animal models of neurodegenerative retinal disease (LaVail et al. 1992; Fakforovich et al. 1990).

To date, there are no approved effective therapies for the treatment of ocular neovascular diseases which do not include the destruction of healthy viable tissue. There are certainly no therapies specifically directed at eliminating or inhibiting the deposition and accumulation of amyloid proteins, drusen or amyloid-like proteins including SAA on the Bruch's membrane in the retina as in ARMD. Such accumulation of amyloid and/or drusen and other lipoproteins including SAA causes retinal dysfunction by several mechanisms including disruption of retinal pigmented epithelial (RPE) cell function due to thickening of Bruch's membrane, and RPE detachment resulting in rapid loss of visual acuity followed by macular atrophy and retinal detachment (Ciulla et al. 1998). Additionally, the deposited drusen and/or amyloid proteins including SAA could exert direct neurotoxic effects on the RPE cells and neighboring cells in the retina akin to the well known toxic effects of such amyloid proteins and amyloid/lipid complexes observed in brain cell death as in Alzheimer's disease (Lambert et al. 1998; Liu and Schubert 1997; Pike et al. 1993; Nakagami et al. 2002) in retina (Jen et al. 1998). Although panretinal photocoagulation is the current medical practice for the treatment of diabetic retinopathy and ARMD and is effective in inhibiting retinal neovascularization, this procedure destroys healthy peripheral retinal tissue. This destruction of healthy tissue decreases the retinal metabolic demand and thereby reduces retinal ischemia driven neovascularization. Photodynamic therapy (PDT) is a procedure in which a photoactivatable dye is given systemically followed by laser activation of the dye in the eye at the site of new blood vessel formation (Asrani & Zeimer 1995; Asrani et al. 1997; Husain et al. 1997; Lin et al. 1994). The photoactivated drug generates free oxygen radicals which seal the newly formed blood vessels and thereby prevent or reduce their growth, at least temporarily. This procedure has been used in patients with the exudative form of macular degeneration and many patients show regression of their subretinal neovascular membranes. Unfortunately, it appears that the PDT-induced inhibition of retinal neovascularization is risky, expensive and provides transient and temporary relief lasting only 6-12 weeks (Gragoudas et al. 1997; Sickenberg et al. 1997; Thomas et al. 1998).

Thus, there is an urgent need for therapeutic methods for altering (by inhibiting or even reversing) the disease processes of glaucoma and ARMD.

SUMMARY OF THE INVENTION

The present invention overcomes these and other drawbacks of the prior art by providing methods to diagnose and compositions to treat ocular hypertension, glaucoma and ARMD. The present invention overcomes these and other drawbacks of the prior art by providing compositions and methods for treating ARMD by sequestering and/or degrading Tanis gene product protein (TGPP) and/or p21^{Waf1/Cop1/Sdi1} gene product protein (p21GPP) in ocular tissues at the back of the eye, specifically at the Bruch's membrane, outer retina, macula and sub-retinal space. In addition, compositions and methods to prevent the generation of TGPP and/or p21GPP and/or to prevent the neurotoxic effects of such gene product proteins are provided to treat ARMD. In one aspect, the present invention provides a method for treating ARMD by administering to a patient in need thereof a therapeutically effective amount of a composition comprising an agent that sequesters TGPP or p21GPP in ocular tissue and/or an agent that degrades TGPP or p21GPP in ocular tissue. Such sequestration and/or degradation modulates the expression of the TGPP and p21GPP, such that the patient's condition is treated. In addition, agents that stop or reduce the initial activation of Tanis and p21^{Waf1/Cop1/Sdi1} genes and/or prevent nerve cell death due to the presence of TGPP or p21GPP would also be useful to treat the patient's ARMD condition. In preferred embodiments, the agent will be a small molecular weight molecule, antibody, protein, peptide, peptidomimetic, or nucleic acid.

Preferably, the agents for use in the compositions and methods of the present invention will mainly be chosen from the following:

Compounds that may be useful for preventing the production of TGPP or p21GPP would include: γ -secretase inhibitors such as talsaclidine (Hock et al. 2003), Xanomeline, 3-(2-6-chloropyrazinyl)-1-azabicyclo(2.2.2)octane (L-689660), 1-benzyl-4-(1-(1 carbamoyl-2-phenylethylcarbamoyl-3-methylbutylcarbamoyl)-2-hydroxy-5-phenylpentyl)carbamic acid tert-butyl ester (L-685458), (4-(m-Chlorophenylcarbamoyloxy)-2-butynyl)trimethylammonium Chloride (McN-A-343), 5-propargyloxycarbonyl-1,4,5,6-tetrahydropyrimidine hydrochloride (CDD-0097), fenchylamine, Z-leu-leu-leu-CHO (MG132), Boc-Phe Ψ Phe-Leu-Val-OMe (WPE-111-31C, where Ψ is the pseudopeptide bond containing the hydroxyethyl group), (MW-11-36C/26A), Boc-Val-Ile-NH—CH(CH₃)—C(=O)—CH(F₂)—C(=O)—NH-Val-Ile-OMe (MW-167), CM-265, lactacystin, DNPS1 and N-[N-(3,5-difluorophenacyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAFT) (Lanz et al. 2003). Other compounds of use may include the statin family, e.g. pravastatin, atorvastatin (see Burns and Duff 2003) and presenilinase inhibitors such as pepstatin A (Xia 2003) and talsaclidine (Hock et al. 2003).

Compounds that may be useful for promoting degradation of TGPP or p21GPP may include glycoaminoglycans and congo red (*J. Neurochem.* 70: 292-298 [1998]).

Compounds that may be useful for promoting sequestration or clearance of TGPP or p21GPP may include gelsolin and ganglioside GM1 (Matsuoka et al. 2003). In addition, antibodies raised against drusen, and/or amyloid proteins and/or against amyloid-like proteins would be useful for sequestration and clearance of the former detrimental pro-

teins as has been shown in the brain (Schenk et al. 1999; Janus et al. 2000; Morgan et al. 2000).

Compounds that may be useful for preventing or diminishing the neurotoxic effects of TGPP or p21GPP include RS-0466 (Nakagami et al. 2002c; Nakagami et al. 2002b), V-type ATPase inhibitors (bafilomycin and concanamycin; Kane et al. 1999), tachykinin peptides and their non-peptide analogs (Yankner et al. 1990), α -lipoic acid (Zhang et al. 2001), propentofylline (Koriyama et al. 2003), glycogen synthase kinase-3 β (GSK-3 β) inhibitors (Eldar-Finkelman 2002; Caricasole et al. 2003), memantine (Frankiewicz and Parsons 1999), mixed cyclin-dependent kinase-GSK3 β inhibitors (Damiens et al. 2001), COX-2 inhibitors (Xiang et al. 2002) and propentofylline (Koriyama et al. 2003).

The present invention further provides a method of treating glaucoma by administering a composition containing a p21 $^{Waf1/Cip1/Sdi1}$ gene product protein (see below) inhibitor and/or inhibitors of CDK1, CDK2, CDK5 and CDK9, and inhibitors of cJAK and ASRK-1 including the following agents: olomoucine, roscovitine, purvalanol, kenpaullone, alsterpaullone, indirubins, flavopiridol, staurosporine and analogs and derivatives of the above compounds.

In one aspect, the present invention provides a method for treating glaucoma by administering to a patient in need thereof a therapeutically effective amount of a composition comprising an agent that interacts with a gene encoding a serum amyloid A (SAA) receptor (SEQ ID NO:12), wherein said interaction decreases the expression of SAA (SEQ ID NO:1).

In another aspect, the present invention provides a method for treating glaucoma by administering to a patient in need thereof a therapeutically effective amount of a composition comprising a Tanis antagonist.

In preferred aspects, the agent for use in the methods of the invention is a peroxisome proliferator-activated receptor α (PPAR α) agonist, tachykinin peptide or non-peptide analogs thereof, or α -lipoic acid. More preferably, the agent is fenofibrate, Wy-14643, (4-chloro-6-(2,3-xylidino)-2-pririmidinylthiol)-acetic acid), ciprofibrate, 2-bromohexadecanoic acid, bezafibrate and ciglitizone, bafilomycin or concanamycin.

In yet another aspect, the invention provides a method for treating glaucoma by administering to a patient in need thereof a therapeutically effective amount of a composition comprising a p21 antagonist.

The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a Tanis antagonist and a pharmaceutical carrier.

DETAILED DESCRIPTION PREFERRED EMBODIMENTS

Glaucoma is a heterogeneous group of optic neuropathies that share certain clinical features. The loss of vision in glaucoma is due to the selective death of retinal ganglion cells in the neural retina that is clinically diagnosed by characteristic changes in the visual field, nerve fiber layer defects, and a progressive cupping of the ONH. One of the main risk factors for the development of glaucoma is the presence of ocular hypertension (elevated intraocular pressure, IOP). IOP also appears to be involved in the pathogenesis of normal tension glaucoma where patients have what is often considered to be normal IOP. The elevated IOP associated with glaucoma is due to elevated aqueous humor outflow resistance in the trabecular meshwork (TM), a small specialized tissue located in the iris-corneal angle of the ocular anterior chamber. Glaucomatous changes to the TM include a loss in TM cells and the

deposition and accumulation of extracellular debris including proteinaceous plaque-like material. In addition, there are also changes that occur in the glaucomatous optic nerve head (ONH). In glaucomatous eyes, there are morphological and mobility changes in ONH glial cells. In response to elevated IOP and/or transient ischemic insults, there is a change in the composition of the ONH extracellular matrix and alterations in the glial cell and retinal ganglion cell axon morphologies.

It has been found that the expression of Serum Amyloid A (SAA) mRNA is significantly upregulated in glaucomatous TM tissues and cells. The differential expression seen has been verified using Affymetrix gene chips by real time quantitative polymerase chain reaction (QPCR). This is the first time SAA has been shown to be expressed in the TM (U.S. application Ser. No. 60/530,430).

Human SAA comprises a number of small, differentially expressed apolipoproteins encoded by genes localized on the short arm of chromosome 11. There are four isoforms of SAAs. SAA1 (SEQ ID NO:2), encoded by SEQ ID NO:1, and SAA2 (SEQ ID NO:4), encoded by SEQ ID NO:3, are known as acute phase reactants, like C-reactive protein, that is, they are dramatically upregulated by proinflammatory cytokines. The 5'UTR promoter regions of SAA1 and SAA2 genes are also provided (SEQ ID NO:12 and SEQ ID NO:13, respectively). SAA3 (SEQ ID NO:5) is a pseudogene and SAA4 (SEQ ID NO:6) is a low level endogenously expressed gene encoding endogenous SAA4 (SEQ ID NO:7). SAA2 has two isoforms, SAA2 α (SEQ ID NO:9), encoded by SEQ ID NO:8, and SAA2 β (SEQ ID NO:11), encoded by SEQ ID NO:10, which differ by only one amino acid. SAA1 and SAA2 proteins are 93.5% identical at the amino acid level (SEQ ID NO:2 and SEQ ID NO:4, respectively) and these genes are 96.7% identical at the nucleotide level (SEQ ID NO:1 and SEQ ID NO:3, respectively).

SAA functions as an apolipoprotein and is expressed in a number of tissues in addition to the liver (Miida et al. 1999). However, over-expression of SAA1 or SAA2 leads to the formation of linear fibrils in amyloid deposits, which can lead to pathogenesis and thus many types of diseases (Uhlar and Whitehead 1999; Liang et al. 1997). SAA plays an important role in infections, inflammation, and in the stimulation of tissue repair. SAA concentration may increase up to 1000-fold following inflammation, infection, necrosis, and decline rapidly following recovery. Thus, serum SAA concentration is considered to be a useful marker with which to monitor inflammatory disease activity. Hepatic biosynthesis of SAA is up-regulated by pro-inflammatory cytokines, leading to an acute phase response. Chronically elevated SAA concentrations are a prerequisite for the pathogenesis of secondary amyloidosis, a progressive and sometimes fatal disease characterized by the deposition in major organs of insoluble plaques composed principally of proteolytically cleaved SAA. This same process also may lead to atherosclerosis. There is a requirement for both positive and negative SAA control mechanisms to maintain homeostasis. These mechanisms permit the rapid induction of SAA expression to fulfill host-protective functions, but they also must ensure that SAA expression is rapidly returned to baseline levels to prevent amyloidosis. These mechanisms include modulation of promoter activity involving, for example, the inducer nuclear factor kB (NF-kB) and its inhibitor IkB, up-regulation of transcription factors of the nuclear factor for interleukin-6 (NF-IL6) family, and transcriptional repressors such as yin and yang 1 (YY1). Post-transcriptional modulation involving changes in mRNA stability and translation efficiency permit further up- and down-regulatory control of SAA protein synthesis to be achieved. In the later stages of the AP response,

SAA expression is effectively down-regulated via the increased production of cytokine antagonists such as the interleukin-1 receptor antagonist (IL-1Ra) and of soluble cytokine receptors, resulting in less signal transduction driven by pro-inflammatory cytokines (Jensen and Whitehead, 1998).

There are several reports suggesting that primary amyloidosis may be associated with glaucoma. For example, it was found that amyloid was deposited in various ocular tissues including the vitreous, retina, choroid, iris, lens, and TM in primary systemic amyloidosis patients (Schwartz et al. 1982). Ermilov et al. (1993) reported that in 478 eyes of 313 patients, aged 25 years to 90 years, with cataracts, glaucoma, and/or diabetes mellitus, 66 (14%) of the eyes contained amyloid-pseudoexfoliative amyloid (PEA). Krasnov et al. (1996) reported that 44.4% of 115 patients with open-angle glaucoma revealed extracellular depositions of amyloid. Amyloidosis was revealed in the sclera in 82% of the cases and in the iris in 70% of the cases. A number of clinical conditions, including Alzheimer's disease, exhibit aberrant amyloid tissue deposits associated with disease. However, amyloids are molecularly heterogeneous and encoded by different amyloid genes. The previous reports are unclear regarding which amyloid(s) are associated with glaucoma.

SAA gene expression is elevated significantly in glaucomatous TM tissues. Increased SAA may be involved in the generation of elevated IOP and damage to the optic nerve leading to vision loss in glaucoma patients.

The Tanis gene (SEQ ID NO:14) is a recently identified gene that encodes a membrane protein (SEQ ID NO:15) said to bind to SAA (Walder et al. 2002). It is believed that therapeutic intervention of the interaction between SAA and its putative receptor, encoded by the Tanis gene, may modulate SAA expression levels and/or receptor-mediated SAA signaling. Methods for the identification of agents that interfere with this interaction and their use for the treatment of ocular hypertension, glaucoma and ARMD are also provided herein.

It has also recently been discovered that a gene called p21^{Waf1/Cip/Sdi1} (SEQ ID NO:16) activates SAA and activates the gene APP that produces amyloid protein which forms plaques in the brain that are hallmarks of Alzheimer's disease (Chang et al 2000; Kindy et al. 1999; Johan et al. 1997). In addition, p21^{Waf1/Cip/Sdi1}-induced gene expression results in over production of extracellular matrix (ECM) proteins including fibronectin-1, plasminogen activator inhibitor, tissue-type plasminogen activator, integrin β 3 (Chang et al. 2000) which may be contributive factors in the glaucomatous situation. Likewise, p21^{Waf1/Cip/Sdi1}-induced connective tissue growth factor and galectin-3 (Chang et al. 2000) may also play significant roles in deposition of ECM proteins and other components of ECM in the anterior eye segment leading to ocular hypertension and glaucoma. Therefore, it is believed that inhibition of p21^{Waf1/Cip/Sdi1} gene would be useful in the treatment of the pathophysiology of glaucoma. Interestingly, since p21^{Waf1/Cip/Sdi1} gene expression results in natural inhibition of cyclin-dependent kinases (CDK) (Chang et al. 2000), and since p21^{Waf1/Cip/Sdi1} was reported to bind c-Jun amino-terminal kinase (cJAK), apoptosis-signal-regulating kinase 1 (ASRK-1) and Gadd45 (Chang et al. 2000), it follows that inhibitors of these kinases would also act as p21^{Waf1/Cip/Sdi1} antagonists. Accordingly, inhibitors of CDK1, 2, 5 and 9, and inhibitors of cJAK and ASRK-1 would be useful for treating ocular hypertension, glaucoma and ARMD. Agents which may modulate the interaction of SAA and its putative receptor and the TGPP or p21GPP include, but are not limited to, peroxisome proliferator-activated receptor α (PPAR α) agonists, tachykinin peptides and their non-peptide analogs, and α -lipoic acid. PPAR α agonists include arachidonic acid, linoleic acid, docosahexaenoic acid, eicosapentaenoic acid, 8(S)-HETE, (\pm)ibuprofin,

indomethacin, leukotriene B₄, meclofenamate, prostaglandin A₁, prostaglandin A₂, prostaglandin D₁, prostaglandin D₂, prostaglandin J₂, 15-deoxy- Δ^{12} -prostaglandin J₂, WY 14643, ciglitizone, carbaprostanacyclin and prostacyclin. Examples of preferred agents for use in the present invention include fenofibrate, WY 14643, (4-chloro-6-(2,3-xylidino)-2-pryrimidinylthiol)-acetic acid), ciprofibrate, 2-bromohexadecanoic acid, bezafibrate, ciglitizone, baflomycin, and cananamycin.

In another aspect the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a Tanis gene product protein inhibitor and/or Tani gene inhibitor or a p21^{Waf1/Cip/Sdi1} gene inhibitor or p21^{Waf1/Cip/Sdi1} gene product protein inhibitor and a pharmaceutical carrier.

The Compounds of this invention, can be incorporated into various types of ophthalmic formulations for delivery to the eye (e.g., topically, intracamerally, or via an implant). The Compounds are preferably incorporated into topical ophthalmic formulations for delivery to the eye. The Compounds may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving a Compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the Compound. Furthermore, the ophthalmic solution may contain an agent to increase viscosity, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. Gelling agents can also be used, including, but not limited to, gellan and xanthan gum. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the Compound in a hydrophilic base prepared from the combination of, for example, carbopol-974, or the like, according to the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

The Compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8. The establishment of a specific dosage regimen for each individual is left to the discretion of the clinicians. The Compounds will normally be contained in these formulations in an amount 0.01% to 5% by weight, but preferably in an amount of 0.05% to 2% and most preferably in an amount 0.1 to 1.0% by weight. The dosage form may be a solution, suspension microemulsion. Thus, for topical presentation 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the discretion of a skilled clinician.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1

Formulation of Tanis Gene (TG) Inhibitor or TG Product Protein Inhibitor or p21^{Waf1/Cip/Sdi1} Gene Inhibitor or Inhibitor of p21^{Waf1/Cip/Sdi1} Gene Product Protein for Topical Ocular Application

1% suspension or solution of Tanis gene inhibitor (TGI) or inhibitor of Tanis gene product protein (TGPP) or p21^{Waf1/Cip/Sdi1} gene inhibitor (p21GI) or inhibitor of p21G product protein (p21GPPI) for topical ocular application:

| Description | Conc. | Units | Purpose |
|---|-----------|-------|--------------------------------------|
| TGI or TGPP or p21GI or p21GPPI | 1% | W/V% | active ingredient |
| hydroxypropyl methylcellulose | 0.5% | W/V % | viscosity modifier (2910) (E4M), USP |
| dibasic sodium phosphate (anhydrous), usp | 0.2% | W/V % | buffering agent |
| sodium chloride, usp | 0.75% | W/V % | tonicity agent |
| disodium edta (edetate disodium), usp | 0.01% | W/V % | chelating agent |
| polysorbate 80, nf | 0.05% | W/V % | wetting agent |
| benzalkonium chloride, nf | 0.01% | W/V % | preservative |
| sodium hydroxide, nf | q.s. pH | W/V % | pH adjust |
| hydrochloric acid, nf | q.s. pH | W/V % | pH adjust |
| purified water, usp | q.s. 100% | W/V % | vehicle |

In similar other examples, TGI or TGPP or p21GI or p21GPPI will be substituted by agents that sequester or degrade the above or agents that prevent the toxic effects of the above.

Methods to measure the potency or efficacy of agents that can inhibit the secretion of SAA from cultured cells involve the use of an enzyme-linked immunosorbant assay (ELISA) for human SAA as described by Yamada et al. (2000) and using human peripheral monocytes and monocytic leukaemic cell-line THP-1. In addition, methods to determine the potency and efficacy of agents to inhibit gene expression of p21^{Waf1/Cip/Sdi1} can be studies using standard methods described by Chang et al. (2000).

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and structurally related may be substituted for the agents described herein to achieve similar results. All such substitutions and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

REFERENCES

The following references, and the bibliography cited within these, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

PUBLICATIONS

Abler et al., RES. COMMUN. MOL. PATH. & PHARM. 92:177-189 (1996).

- Ambati, J. et al., *Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies*. Surv. Ophthalmol. 48: 257-293 (2003).
- Asrani et al., INV. OPHTHALM. VIS. SCI. 38(13):2702-2710 (1997).
- Asrani and Zeimer, Br. J. OPHTHALM. 79(8):776-780 (1995).
- Bressler et al., SUR. OPHTHALM. 32:375-413 (1988).
- Brown, M., *Gene therapy success for Alzheimer's?* DRUG DISCOV. TODAY 8:474-475 (2003).
- Caricasole, A. et al., *The Wnt pathway, cell-cycle activation and β-amyloid; novel therapeutic strategies in Alzheimer's disease?* TRENDS PHARMACOL. SCI. 24:233-238 (2003).
- Chabry J. et al., *In vivo and in vitro neurotoxicity of the human prion protein (PrP) fragment P1118-135 independently of the PrP expression*, J. NEUROSCI. 23:462-469 (2003).
- Chang, B-D. et al., *Effects of p21^{Waf1/Cip/Sdi1} on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases*, PROC. NAT. ACAD. SCI. USA 97:4291-4296 (2000).
- Ciulla et al., SUR. OPHTHALM. 43:134-146 (1988).
- Curcio et al., INV. OPHTHALM. VIS. SCI. 37:1236-1249 (1996).
- Fakforovich et al., NATURE 347:83-86 (1990).
- Ge-Zhi et al., TRANS. AM. OPHTHALM. SOC. 94:411-430 (1996).
- Gragoudas et al., INV. OPHTHALM. VIS. SCI. 38(4)S17 (1997).
- Hock, C. et al., *Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of Aβ₄₂ in patients with Alzheimer's disease*, AMYLOID: J. PROT. FOLD. DISORD. 10:1-6 (2003).
- Husain et al., OPHTHALM. 104(8):242-250 (1997).
- Janus, C. et al., *AB peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease*, NATURE 408:979-982 (2000).
- Jen, L. S. et al., *Alzheimer's peptide kills cells of retina in vivo*, NATURE 392:140-141 (1998).
- Jensen L E and Whitehead A S, BIOCHEM. J. 334:489-503 (1998).
- Johan, K. et al., *Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils*, PROC. NAT. ACAD. SCI. USA 95:2558-268 (1997).
- Kane, M. D. et al., *Inhibitors of V-type ATPases, baflomycin A1 and concanamycin A, protect against β-amyloid-mediated effects on 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction*, J. NEUROCHEM. 72:1939-1947 (1999).
- Kindy, M. S et al., *Apolipoprotein serum amyloid A in Alzheimer's disease*, J. ALZHEIMER'S DISEASE 1:155-167 (1999).
- Koriyama, Y. et al., *Propentofylline protects β-amyloid protein-induced apoptosis in cultured rat hippocampal neurons* EUR. J. PHARMACOL. 458:235-241 (2003).
- Kumon, Y., Hosokawa, T., Suchiro, T., Ideda, Y., Sipe, J. D., and Hashimoto, K., *Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells*, AMYLOID 9:237-241 (2002a).
- Kumon, Y., Suchiro, T., Faulkes, D. J., Hosokawa, T., Ideda, Y., Woo, P., Sipe, J. D., and Hashimoto, K., *Transcriptional regulation of Serum Amyloid A1 gene expression in human aortic smooth muscle cells involves CCAAT/enhancer binding proteins (C/EBP) and is distinct from HepG2 cells*, SCAND. J. IMMUNOL. 56:504-511 (2002b).
- Kumon, Y., Suchiro, T., Hashimoto, K., and Sipe, J. D., *Dexamethasone, but not IL-1 alone, upregulates acute-phase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells*, SCAND J. IMMUNOL. 53:7-12 (2001).
- Lambert, M. P. et al., *Diffusible, nonfibrillar ligands derived from Aβ₁₋₄₂ are potent central nervous system neurotoxins*, PROC. NAT. ACAD. SCI. USA 95:6448-6453 (1998).
- Lanz, T. A. et al., *The γ-secretase inhibitor N-(N-(3,5-difluorophenacetyl)-L-alanyl)-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid*

11

- in young (plaque-free) and aged (plaque-bearing) Tg2576 mice* J. PHARMACOL EXPT. THER. 305:864-871 (2003).
- LaVail et al., PROC. NAT'L ACAD. SCI. 89:11249-11253 (1992).
- Liang, J. S., Sloane, J. A., Wells, J. M., Abraham, C. R., Fine, R. E., and Sipe, J. D., *Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain*, NEUROSCI. LETT. 225:73-76 (1997).
- Lin et al., CURR. EYE RES. 13(7):513-522 (1994).
- Liu, Y and Schubert, D., *Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis*, J. NEUROCHEM. 69:2285-2293 (1997).
- Marks, N. and Berg, M. J., *APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (Tgs) and transfected cells*, NEUROCHEM. RES. 28:1049-1062 (2003).
- Matsuoka, Y. et al., *Novel therapeutic approach for the treatment of Alzheimer's disease by peripherally administration of agents with an affinity for β-amyloid*, J. NEUROSCI. 23:29-33 (2003).
- Miida T., Yamada, T., Yamadera, T., Ozaki, K., Inano, K., Okada, M., *Serum amyloid A protein generates pre-beta 1 high-density lipoprotein from alpha-migrating high-density lipoprotein*, BIOCHEM. 38(51):16958-16962 (1999).
- Morgan, D et al., *Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease*, NATURE 408:982-985 (2000).
- Naash et al., INV. OPHTHALM. VIS. SCI. 37:775-782 (1996).
- Nakagami, Y and Oda, T., *Glutamate exacerbates amyloid β1-42-induced impairment of long-term potentiation in rat hippocampal slices*, JPN. J. PHARMACOL. 88:223-226 (2002a).
- Nakagami, Y. et al., *A novel-sheet-breaker, RS-0406, reverses β-amyloid-induced cytotoxicity and impairment of long-term potentiation in vitro*, Br. J. PHARMACOL. 137:676-682 (2002b).
- Noell et al., INVEST. OPHTHALM. VIS. SCI. 5:450-472 (1966).

12

- O'Hara, R., Murphy, E. P., Whitehead, A. S., FitzGerald, O., and Bresnihan, B., *Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue*, ARTHRITIS RES. 2:142-144 (2000).
- Pike, C. J. et al., *Neurodegeneration induced by β-amyloid-peptides in vitro: the role of peptide assembly state*, J. NEUROSCI. 13:1676-1687 (1993).
- Schenk, D. et al., *Immunization with amyloid-β attenuates Alzheimer's-disease-like pathology in the PDAPP mouse*, NATURE 400:173-177 (1999).
- Sickenberg et al., INV. OPHTHALM. VIS. SCI. 38(4):S92 (1997).
- Taylor et al., ARCH. OPHTHALM. 110:99-104 (1992).
- Thomas et al., INV. OPHTHALM. VIS. SCI. 39(4):S242 (1998).
- Thorn, C. F. and Whitehead, A. S., *Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA*, J. IMMUNOL. 169:399-406 (2002).
- Uhlar, C. M., and Whitehead, A. S., *Serum amyloid A, the major vertebrate acute-phase reactant*, EUR. J. BIOCHEM. 265:501-523 (1999).
- Urieli-Shoval, S., Cohen, P., Eisenberg, S., and Matzner, Y., *Widespread expression of serum amyloid A in histologically normal human tissue. Predominant localization to the epithelium*, J. HISTOCHEM. CYTOCHEM. 46:1377-1384 (1998).
- Walder et al., *Tanis: A link between type 2 diabetes and inflammation?* DIABETES 51:1859-1866 (2002).
- Xia, W., *Relationship between presenilinase and γ-secretase*, DRUG NEWS PERSPECT. 16:69-73 (2003).
- Yamada et al., *Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes*, SCAND. J. IMMUNOL. 52:7-12 (2000).
- Yamazaki et al., BIOCHEMICAL AND BIOPHYSICAL RES. COMM., 290:1114-1122 (2002).
- Young, SUR. OPHTHALM. 32:252-269 (1988).
- Zhang, L. et al., *α-Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signaling pathway*, NEUROSCI. LETT. 312:125-128 (2001).

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 17

<210> SEQ ID NO 1
<211> LENGTH: 369
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

| | |
|--|-----|
| atgaagcttc tcacggccct ggttttctgc tccctggtcc tgggtgtcag cagccgaagc | 60 |
| ttctttcggt tccttggcga ggctttgtat ggggctcgaa acatgtggag agcctactct | 120 |
| gacatgagag aagccaatta catcggtca gacaaatact tccatgctcg gggaaactat | 180 |
| gatgctgccaa aaaggggacc tgggggtgtc tgggctgcag aacgcgtcag cgatgcaga | 240 |
| gagaatatcc agagattctt tggccatggt gcccggact cgctggctga tcaggctgcc | 300 |
| aatgaatggg gcaggagtgg caaagacccc aatcaacttcc gacctgctgg cctgcctgag | 360 |
| aaataactga | 369 |

<210> SEQ ID NO 2
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

-continued

<400> SEQUENCE: 2

```

Met Lys Leu Leu Thr Gly Leu Val Phe Cys Ser Leu Val Leu Gly Val
1           5          10          15

Ser Ser Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
20          25          30

Arg Asp Met Trp Arg Ala Tyr Ser Asp Met Arg Glu Ala Asn Tyr Ile
35          40          45

Gly Ser Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys
50          55          60

Arg Gly Pro Gly Gly Val Trp Ala Ala Glu Ala Ile Ser Asp Ala Arg
65          70          75          80

Glu Asn Ile Gln Arg Phe Phe Gly His Gly Ala Glu Asp Ser Leu Ala
85          90          95

Asp Gln Ala Ala Asn Glu Trp Gly Arg Ser Gly Lys Asp Pro Asn His
100         105         110

Phe Arg Pro Ala Gly Leu Pro Glu Lys Tyr
115         120

```

<210> SEQ ID NO 3

<211> LENGTH: 570

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 3

```

agggaccgc agctcagcta cagcacagat cagcaccatg aagcttctca cgggcctgg 60
tttctgctcc ttggtcctga gtgtcagcag ccgaagcttc ttttcgttcc ttggcgaggc 120
ttttgatggg gctcgggaca tgtggagagc ctactctgac atgagagaag ccaattacat 180
cggctcagac aaatacttcc atgctcgggg gaactatgtat gctgccaaaa ggggacctgg 240
gggtgcctgg gccgcagaag tgatcagcaa tgccagagag aatatccaga gactcacagg 300
ccatggtgcg gaggactcgc tggccgatca ggctgccaat aaatggggca ggagtggcag 360
agaccccaat cacttccgac ctgctggct gcctgagaaa tactgagctt cctcttcact 420
ctgctctcag gagacctggc tatgaggccc tcggggcagg gatacaaagt tagtgaggc 480
tatgtccaga gaagctgaga tatggcatat aataggcatc taataaatgc ttaagaggc 540
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 570

```

<210> SEQ ID NO 4

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 4

```

Met Lys Leu Leu Thr Gly Leu Val Phe Cys Ser Leu Val Leu Ser Val
1           5          10          15

Ser Ser Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
20          25          30

Arg Asp Met Trp Arg Ala Tyr Ser Asp Met Arg Glu Ala Asn Tyr Ile
35          40          45

Gly Ser Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys
50          55          60

Arg Gly Pro Gly Gly Ala Trp Ala Ala Glu Val Ile Ser Asn Ala Arg
65          70          75          80

Glu Asn Ile Gln Arg Leu Thr Gly His Gly Ala Glu Asp Ser Leu Ala
85          90          95

```

-continued

Asp Gln Ala Ala Asn Lys Trp Gly Arg Ser Gly Arg Asp Pro Asn His
100 105 110

Phe Arg Pro Ala Gly Leu Pro Glu Lys Tyr
115 120

<210> SEQ_ID NO 5
<211> LENGTH: 4286
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 5

| | | |
|---|--|------|
| gatggttgac aactccccc | ctttcccccc tcttctactg tctactcctg ggaccaagt | 60 |
| agccacgcca gctcagatac tacactgacc acaggaaatc ccacctttc caaggaatgg | | 120 |
| aagttgtgta gggaatattc aaatgttgct tagcattgcc ttagataaga accaaaggaa | | 180 |
| cagggaaatc ctctgacagc tatctgcctt ataactttca ttttactgtg cctaaaatat | | 240 |
| gctcagaacc cagaaagagg cataattcct aattttggca ggctctaatac taaaataatg | | 300 |
| atttc当地 atgggtgac ttttgtctat ttgctttatc ctgggtcaact gtcctcttc | | 360 |
| tgtcagatac tgggattcca atgagacaaa tggaaatgga gacgtagacc ctctgacc | | 420 |
| ctatcttttata tctatacaca tacacctgtg tgtgtgtgtg tgtgtgtgtg tgtgcgtgt | | 480 |
| taaaaccgag tgggtttttt tcttggaaatg aaagaatgga ctaacattac aaaaaataaa | | 540 |
| aacttggaaac agaatgtgta ttatccctgg ttgtgtttcc ttggccctgc agcaggatga | | 600 |
| agctctccac tggcatcatt ttctgctccc tggcctggg tgtcagcagc caaggatgg | | 660 |
| taacattcct caaggcagct ggccaaagggtg aggtccacag gatagggggc aggaggctgc | | 720 |
| ttctggctgc ccccaggatg cagctgagca gaggccacat cccactggg caaagggtg | | 780 |
| agtgtgcca cagatggata gagaaggggc atggttttc ataagcgtgg ttccatgc | | 840 |
| ttttctggac agctttgaca ctcttctatg aggatcctcc agccgaggc gcataagg | | 900 |
| ttagctgcct cttttcagca ggaccatgag agagatgtgg agttgagggg tgcatgtcc | | 960 |
| cataataccg gtggggctct actgccccct agtggaaat ctggcacagt tcatgtctat | | 1020 |
| gtctcctggg aagccaggaa gcaggtggat caaaagtgtg aggcgagtc atgggaaagc | | 1080 |
| tgaacggagc caaccgtccc cataaaaaca accaagctta gctgagattt taatacgtac | | 1140 |
| taggcactgt taaaatgtac taatgaattt gttccatca ttttagtcata tgatgcaagc | | 1200 |
| agcattatcc cttAACAGAG aagctaACAC acACACACAC acACACACAC taACACACAC | | 1260 |
| acACACACAC acACACACAC aaACCCCAAG atACGTAAG aAGTCCAAA GCAGAGCAGG | | 1320 |
| attaACCCAG GCAGTCTTGC TCTGCAGAAC TTGCTTTAA TCAAGGTACT CTGCTGCTT | | 1380 |
| caAAACAAGA GTTTCGGATT TGTGAACACA TAGCTCATCC TTTATCTAAG AAATGGCAA | | 1440 |
| taggatgtgg tgcctttgga aggttaagtct agtccactt atccagtaa aacctacagt | | 1500 |
| gaattacctt gatggtggtt ctactggggc ttatatatgg ccagggaaact gctagcaaga | | 1560 |
| gaaatatacc ccgaggcgtg ggcacagtg gtcacacctg taatcccagc actttggag | | 1620 |
| gctgaggtgg gcagatcacc tgaggtcaag agttcgagac cagcctggcc aacatggcga | | 1680 |
| aatccctgtct ctactaaaaa tacagaaatt agccgggtgt ggtggcatgc gcctataatc | | 1740 |
| ccagcctctc gggaggctga gggagaagaa ttgcttgaac tcaggaggca gaggttgcag | | 1800 |
| tgagctgtga tcacaccact gcactccagc ctaggagaca gagcaagact ccatctagag | | 1860 |
| agacagagag agagagagag ggagaaatat accccactag ccataataaa gtggcaa | | 1920 |

-continued

| | |
|---|------|
| tttgtttca gaatgcagta ttttaaattt caggtattat tattttctg agtctctgaa | 1980 |
| aatgggtttt aaggatttgc ttttaatcct atttacatgt tcacacactc aactacaat | 2040 |
| atcttcatt ccttaggtta atattttca aagggttgtt ctgggaccac ttgcgtgaga | 2100 |
| atcacctgga ttctggatg ctgtgtaaa tgaaatgaag attcccggtt ccataacccta | 2160 |
| ccccctgccc ccaacagcca cagtctcttg ggacagagcc tagaaatctt gccttgcta | 2220 |
| agcacctcg tagattttta tgcacagcaa aggttgagaa ccactacctc ttgtttgct | 2280 |
| gctgaaagtg ataaaatgtg ccaggaattt tggaagtact tattaagcca atctgaacat | 2340 |
| caaggagcca tttaaagttag taactcagag gaataagtag agtaaaaatg tcataaactc | 2400 |
| tcaataaaag caatcaattt aacaccagga gtaataaaatg cataaaatga agatgagtt | 2460 |
| tctaatacagaa aaatttatata aaccatgatt ataactctat atttgagttc cccctttcc | 2520 |
| gtaatcagtt aattttctaa aaaatcttcg tcacttaatt ctatgtat cagatccctt | 2580 |
| cagtccgtaa ctccctgctc ctcatcttag tttagccctt ctttttctt atgccacctt | 2640 |
| tcctaaggac cagagaagtg aaatgataat atattggcca cctacaatgt tctagacatc | 2700 |
| atacatgtat ttctctgtct cttctgcata atcaactgtga ggcaggcaat actcctccat | 2760 |
| ttcattgggg aggacattga ggttctgaac tagtgggtca gttgtcctt ttctgaattt | 2820 |
| gattacccag tagtataaag ctttcttagg taactcacct ttatcacttg ctgactgaat | 2880 |
| tctgacagat gtcagttct aattatagcc tggacattca gatgtattca ggaccaagtt | 2940 |
| gtcctcactc tacctacagg catgaatttc tctcattgac taggttagga gcccataatg | 3000 |
| tctgcagcct ccctcagaat cccctgtgtt ctcacaccag ggaactgagg gttccctggg | 3060 |
| tccttccagg tagaagttca ttgtacaatg aaacatccct taaggaccat ttcatcttt | 3120 |
| ctttaggtgc atcacacatg gttaaaacaa agtaataaca gaacttagaa tggaatcaa | 3180 |
| cagaatgaaa cttacaccaa gtacaattct cattacatta acccagagaa gtaaaaagta | 3240 |
| gaagaatatt tatttcaagc caatataatt tccaagggtt ttgttgaagg ctgaaatctt | 3300 |
| cgggaggaaa gtagtgagaa gaaaactgtt cattcctcta tttccctgt atataattgt | 3360 |
| tttgatcatt ttcttcctt tccagggact aaagacatgt ggaaagccta ctctgacatg | 3420 |
| aaagaagcca attacaaaaa attcagacaa atactccat gcttggggaa actatgatgc | 3480 |
| tgtacaagg gggcttgggg ctgtctggc tacagaagtg atcaggtat gcacattcct | 3540 |
| gatgttgcca ggaatgagtg agcagagctt gactgcctt gacagtcagg agagaggtaa | 3600 |
| gctccttgca gagaagtttag aggctgcagc ccctcctctt cttgcctctt ctctgcctgt | 3660 |
| gtgcttagtg cgagggtctg agtggatggt agaagtgtt gattcctcac cctcccttc | 3720 |
| tgggtgtgt tcatccagcc taggggtgcc cagcctgqct gagtggggca gtgccaggc | 3780 |
| agggtcattt ttttcacccc tccttccttg gccttcctgg gcttctccca gagtcctccc | 3840 |
| ttggaaagca gagaatggga aggtgggttg ttgctcaactg gcctgggtat taatctcctt | 3900 |
| gcttccttgg actacagcga tgccagagag aacgtccaga gactcacagg agaccatgca | 3960 |
| gaggattcgc tggctggcca ggctaccaac aaatggggcc agagtggcaa agacccaaat | 4020 |
| cacttccgac ctgctggcct gccagagaaa tactgagctt cctttcaat ctgctctcag | 4080 |
| gagacctggc tgtgagcccc tgagggcagg gacatttggt gacccatgt tactgaattc | 4140 |
| tatatcccta gtacttgata tagaacacat aaaaatgctt aataaatgct tgtgaaatcc | 4200 |
| agtttggat tggaaatctgg aagcagaata tgacagtctt cctggatca tggcctgtt | 4260 |
| tagtaccata gggatgacca ataaac | 4286 |

-continued

<210> SEQ ID NO 6
<211> LENGTH: 193
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 6

```
gttttctgct ccttggtcct ggggtgcagc agccgaagct tctttcggt ccttggcgag      60
gcttttgatg gggctcgaaa catgtggaga gcctactctg acatgagaga agccaattac      120
atcggctcag acaaatactt ccatgctcgg gggaaactatg atgctgccaa aaggggacct      180
gggggtctgg gct                                         193
```

<210> SEQ ID NO 7
<211> LENGTH: 64
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 7

```
Val Phe Cys Ser Leu Val Leu Gly Val Ser Ser Arg Ser Phe Phe Ser
1           5               10          15

Phe Leu Gly Glu Ala Phe Asp Gly Ala Arg Asp Met Trp Arg Ala Tyr
20          25               30

Ser Asp Met Arg Glu Ala Asn Tyr Ile Gly Ser Asp Lys Tyr Phe His
35          40               45

Ala Arg Gly Asn Tyr Asp Ala Ala Lys Arg Gly Pro Gly Gly Leu Gly
50          55               60
```

<210> SEQ ID NO 8
<211> LENGTH: 369
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 8

```
atgaagcttc tcacggcct ggtttctgc tccttggtcc tgagtgtcag cagccgaagc      60
ttctttcgt tccttggcga ggctttgat gggctcgaa acatgtggag agcctactct      120
gacatgagag aagccaatta catcggtca gacaaatact tccatgctcg gggaaactat      180
gatgctgccaa aaaggggacc tgggggtgcc tggggccgac aagtgtatcg caatgccaga      240
gagaatatcc agagactcac aggccatggt gcggaggact cgctggccga tcaggctgcc      300
aataaatggg gcaggagtggtt cagagacccc aatcaattcc gacctgtgg cctgcctgag      360
aaatactga                                         369
```

<210> SEQ ID NO 9
<211> LENGTH: 122
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 9

```
Met Lys Leu Leu Thr Gly Leu Val Phe Cys Ser Leu Val Leu Ser Val
1           5               10          15

Ser Ser Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
20          25               30

Arg Asp Met Trp Arg Ala Tyr Ser Asp Met Arg Glu Ala Asn Tyr Ile
35          40               45

Gly Ser Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys
50          55               60
```

-continued

Arg Gly Pro Gly Gly Ala Trp Ala Ala Glu Val Ile Ser Asn Ala Arg
65 70 75 80

Glu Asn Ile Gln Arg Leu Thr Gly His Gly Ala Glu Asp Ser Leu Ala
85 90 95

Asp Gln Ala Ala Asn Lys Trp Gly Arg Ser Gly Arg Asp Pro Asn His
100 105 110

Phe Arg Pro Ala Gly Leu Pro Glu Lys Tyr
115 120

<210> SEQ ID NO 10

<211> LENGTH: 369

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 10

| | | | |
|------------------------|------------------------|-----------------------|-----|
| atgaagcttc tcacgggccc | ggttttctgc tccttggtcc | tgagtgtcag cagccgaagc | 60 |
| ttcttttcgt tccttggcga | ggcttttgcgt ggggctcggt | acatgtggag agcctactct | 120 |
| gacatgagag aagccaattta | catcggtca gacaaataact | tccatgctcg gggaaactat | 180 |
| gatgctgccca aaaggggacc | tgggggtgcc tggggccgcag | aagtgtatcg caatgccaga | 240 |
| gagaatatcc agagactcac | aggccgtggt gcggaggact | cgctggccga tcaggctgcc | 300 |
| aataaatggg gcaggagtg | cagagacccc aatcaattcc | gacctgctgg cctgcctgag | 360 |
| aaatactga | | | 369 |

<210> SEQ ID NO 11

<211> LENGTH: 122

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 11

Met Lys Leu Leu Thr Gly Leu Val Phe Cys Ser Leu Val Leu Ser Val
1 5 10 15

Ser Ser Arg Ser Phe Phe Ser Phe Leu Gly Glu Ala Phe Asp Gly Ala
20 25 30

Arg Asp Met Trp Arg Ala Tyr Ser Asp Met Arg Glu Ala Asn Tyr Ile
35 40 45

Gly Ser Asp Lys Tyr Phe His Ala Arg Gly Asn Tyr Asp Ala Ala Lys
50 55 60

Arg Gly Pro Gly Gly Ala Trp Ala Ala Glu Val Ile Ser Asn Ala Arg
65 70 75 80

Glu Asn Ile Gln Arg Leu Thr Gly Arg Gly Ala Glu Asp Ser Leu Ala
85 90 95

Asp Gln Ala Ala Asn Lys Trp Gly Arg Ser Gly Arg Asp Pro Asn His
100 105 110

Phe Arg Pro Ala Gly Leu Pro Glu Lys Tyr
115 120

<210> SEQ ID NO 12

<211> LENGTH: 10001

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 12

| | | | |
|--------------------------|-----------------------|-----------------------|-----|
| gggtggatca cgaggtcagg | agatcgagac catcttggct | aacatggta aaccccgct | 60 |
| ctactaaaaaa tacaaaaaaaaa | ttagccgggc gtcatggtgg | gcgctgttag tcccagctac | 120 |
| tcgggaggct gagggcaggag | aatggtgtga acccgggagg | cagaacttgc agtgagccta | 180 |

-continued

| | |
|--|------|
| gatcgcgcca ctgcactcca gcctggggga caaaacgaga ctctgtctca aaaaaaaaaa | 240 |
| aaaaaaattcc cacattagag ttggggaaat gggcagtctt ggtgaaagtt agggAACAGA | 300 |
| tctgggacac gttatacgcca gctggactac aggaggccat aagctcaatt cttccttgac | 360 |
| tctgaaacct tccactggtc ctaatgccta gtaattccag gccttcccag tttgtgccag | 420 |
| gcttggaggt gaacacatct atgtgccaag aaggaaaggt atgccaagca ggggcttaag | 480 |
| tcatccttat cctcagtcgt tctatgagtg gtatgtaccc ctgttcccct tgcaagatct | 540 |
| gctgggctta ggtctcctgg ctgtgagttc cccatacctg ggcataaaatg tagtgagcct | 600 |
| gagctcccaa ataagggttgg gggctccaga gaggtggaga gccctgtgtc tggaaagtgt | 660 |
| gccccccag caggtctgac caggaagata cactgctagg gttatggaaa aagactatgt | 720 |
| gtcaaggctt cttgatttctt catctaggca gagaatcatc ttttaattaat gggaaactgg | 780 |
| aaggcaaatt acttggaccc gaaattactt tttgtttatt gaaccactgt gttgtaaatc | 840 |
| acatctctctt gaaggcaaga gaaatcagg agttacaaaaa tgtttaggag aactaaacag | 900 |
| gactccctgt tttgctaact aatcagattt agacaggctc tctggtaaat ctacaattt | 960 |
| gatgttgttc aaccataagc agttaatttc ctatgcttga ttttccgtac aatgaatgt | 1020 |
| aaaggaaaag gagtcctttt gacaaaatat tttattgttc atctaaactg aaaaacttct | 1080 |
| ctattttca aaattgctat acgtgtttaa agatgttagat atttgaatag ccttaactgg | 1140 |
| acagaagggtt taatgtatgc tcctaagaca tacctataaa ttacttgaaa ttgaaacgaa | 1200 |
| atttaagaag aattatttggaa attttccctt tctcaaatttga gttcttagtt tcataaatac | 1260 |
| tatacaagtc cataagagat ttggggttt gagatgtttt tttttttt ttttttcag | 1320 |
| acggagtttc actgttgttgc cctaggctgg agtgcaatgg cgtgacctca gctcaactaca | 1380 |
| acctccaccc cccaggttca agcgattttc ctgcctcagc ctcccaagta gctgggattt | 1440 |
| cagggacctg ccacaacgcc aagctaatgt tttgtatttt tagtagagat ggggttcacc | 1500 |
| atgttggcca ggcttgcgtg gaactcctga cctcagggtga tccacccgccc tataatttt | 1560 |
| tactcccttt tgcaaattttt tgaaaaggaa taaagtgc当地 tattttaaa cagaatgc当地 | 1620 |
| agttctgttg tcctttggca ataccagttt cagactctga gagtggtctt tgctgttgc当地 | 1680 |
| gacagtgggc tcatgaccaatccat gccccccgtg cgagtccttc ataacctgtat | 1740 |
| tcagtc当地 ctttagaggcc agcaggcttc agggaggcgt gaggcctcagc caacaacccata | 1800 |
| taggggaaga gacgc当地 gac tcaatgc当地 caggtttggaa ttctgggtgc当地 tagagaatgc当地 | 1860 |
| aacttggaaa ctctgaggcc ggagaaaagg gttctcttc catgagagag tgtggctt | 1920 |
| gtgagaagcg acacacagca aacacaatttta agagtccacc cctcagcggg ggc当地gggc当地 | 1980 |
| tcacgc当地gtt aatcccagca ctggggagg cc当地ggc当地ggg tggatcacga ggtcaggaga | 2040 |
| tcaagaccat cctggcttaac acagtggaaac cctgtctcttta ctaaaaatac aaaaaaaaaatttta | 2100 |
| gccccccgtg gtggcgggccc cctgtgggtcc cagctactcg ggaggctgag gcaggagaat | 2160 |
| ggtgtgaacc cgggagggtgg agctgc当地t gaggccagat cgc当地ccactg cactccagcc | 2220 |
| tgggc当地acag agcgagactc catctcaaaa aaaaaaaaaaaaagaa aaagaaaaaaag aaaaagagtc当地 | 2280 |
| cgc当地ccctgaa ttaaatagtt ggtccttttgc tggctctgggt gattcacttg ctaagtggaa | 2340 |
| gaaacaggag ggaatctttt ctc当地tgc当地t cctggtaatc catagcccat ggc当地tggctt | 2400 |
| tacttctgttta aagtggcagg agaccttttgc acagctgagc catttcttat tttatatttt | 2460 |
| ttaataaagag atggtaggaa tgagcaatgc当地 tatttagtacc tggggactgt tggtcttaag | 2520 |

-continued

| | |
|---|------|
| gagaaaacaat cttagaatga tttagtgatac cccttgctt ctcttttctt tcattataact | 2580 |
| ttttgtacac atattttcc catttattta ttgaaatctt actgatttat tataagtata | 2640 |
| agctttatgt ctacacatgt ataatcattt ttccccaaatg ataagtctct ttttcatgga | 2700 |
| ggcacagcct agacctgggtt agccgccttc tcccctcatt gtatgcccaa tatctattgt | 2760 |
| agtatctgct gcatagaagg cactcgatgc gtgaatggat aatgactgat gatgaatcaa | 2820 |
| taaataaaatg gacatgtcat tgtaaaaaat tctaaaaatc tagaataaca caagctgtg | 2880 |
| gcactaccta gaaacacaga tgtaaaactt cctaggttgtt gtttaccat gggAACATGT | 2940 |
| ctttgaacaa aaatgggatc atattctatt gcactcttc ccttaagaga tacttctcca | 3000 |
| ggtcattaag tgctcttcca caatatcagt atatggcaga ggcaaggta taccaggct | 3060 |
| gtctgaaacc agggcttggc tcttaacttg cagccatact gcctccaagt ctaggtggct | 3120 |
| gggttttagg atctgtaatg ggaactcagt gtcacaacctt ctactggaa ggtattctgg | 3180 |
| tgttcataa caggacttcc tggtagagat aaccatggca aaatggaata gagacaaagt | 3240 |
| tcaggtttct gctgccagga gctgagattt ctgtgaccaa tggcattctc ccaaaccaaa | 3300 |
| taatccaacc tggaaattacc ataaaccact cctcatctt tcaagggttg tccaagttcc | 3360 |
| cagaaaagaa catttgttaa gggatggagg caaggaggtg gagaagaaag agcactggcc | 3420 |
| aaggatcat gagtgccctg gtttctggc cttgaataag ccatttatct tctctgcagc | 3480 |
| ttctccatct gataggagtt tggaggcaga gttttttctt aatgagcaaa agacagtcgt | 3540 |
| gcctaggaga tgtgggtgtac atgttagaaa gaagggactg gctgtgactc tataaaagat | 3600 |
| gaattcatac aaaaacaaat tacccttcc cagggagaaa gtttggatcc agtaattaga | 3660 |
| gatctcaaaa agtagaagac ctgcctgtg aggccctgtgg cctccaagtt tgaatgctgt | 3720 |
| gtgtcagctt taaaaactag ttttttgctg ataaatgttt catattaagc atgtgtttag | 3780 |
| agtactcctt gcctacccctc actagccact gtttccttcc ctcctccct tgccttcata | 3840 |
| ttctctccag aactttctgc taacttccat tctcttcagg acttcagcat gtttgggaga | 3900 |
| agatcagaaa ggcatcctca ctgtttttt ttttagtccac ttgacctttg gggagtagtt | 3960 |
| ccactggctc ataagtatca gccccccata gcacagcacc ccacactgag cccggaagca | 4020 |
| ataaaagaatc ccaatctgct gtcactaacc agcacgctca actgccatgc ctttactct | 4080 |
| tctcatctcc ctgctttcac gtcacacccaa ctaatttctc tatgagtcag cctcaactct | 4140 |
| cccaacactc tgccccccct tcttctacta cttccagtg agctcctcga aagaagggtc | 4200 |
| tgcggtgagg atgccccctt atctctgcct atttccttcc cattacaaaa acttggaaacc | 4260 |
| tgcctttccc atgttgattt cactttattt tcatcttac ccatgggtt tgccttcgtc | 4320 |
| aatttctccat agacaataga atgagaaaaga ggggtcctcg tcctcttgc tttccatgac | 4380 |
| catttctcca ttcttcaccc ctgtgatgtg tcctcttga agtccctgat aaattcatta | 4440 |
| ccaccttctc tccagtcata ctaatgttat ctgcacaagt gattccaaa caggaagatt | 4500 |
| ttcaaacaact gattcctgaa gatcaccccc aactcgctga actgagacca agacctccaa | 4560 |
| gattatggct taggaatctg cattttttt ttttttttga gacaagagtc tcgctctgtt | 4620 |
| gccaggctag agtgcaatgg tggaatcata gctcattgtt acctcaaact cctggctca | 4680 |
| agtatcttc ctgcctcagc ctcccaagta gtgaggacaa caggagtgtg ccaccatgcc | 4740 |
| cagctaattt gtaattttttt gtagaaatgg agtctcaacta tggctcggtt gctggctca | 4800 |
| aactcctgac cttaaaccat cttccgcctc cgccccaaa agtggggaa ttacagggtt | 4860 |
| gagccaccgt gcccagccta gaaataccca ctgtgtttttt ctgtgttagac aatctgctta | 4920 |

-continued

| | |
|---|------|
| gtgatgtttg gagacaaagt accttttat tgtattcatt gacaaaactc tccagtcctc | 4980 |
| tcccatcttc atggaaaatt ttcacagttc atttacggcc ctcttccaa cacattcact | 5040 |
| gccaatactc ttattgacaa taactgtatt gttgaacctt ccagtatcct gcattcccg | 5100 |
| atcaaggccc cctcaaagcc ctgatatgca aatatctggg aaaagaatgt tccagaggaa | 5160 |
| aggaacagct aatccgagggc cccttagggta agatgtgcct gggggttgg agaccagtgt | 5220 |
| ggccagagca aaatgagcag gaggagagaa ttggatgatg aggtacgaga ggaaggagtt | 5280 |
| aggacagttt gagtaaagtt tgaaaaccat tataagggtt ttgacttcaa ctatgagttg | 5340 |
| aagtggaaatc ctccggagag ttttgaatgg agagtgatag aagttgtctt gtgttgtaac | 5400 |
| agtctggctg ctatactgaa aagagactag ttggcggcaa agggggaaat gtggaaagcca | 5460 |
| gttaagaagc catcataacc cagaaggtga tgcctaataa catctctctg ggagcagcgg | 5520 |
| agagatgata agggtttgcc ttctgaatat gtttttgac aattaatgt aacatttcaa | 5580 |
| gtaggctgag attttattgc atattaacaa tgtccatgtt cactcgccgc agccgcccc | 5640 |
| ttctgcgcgg tcatgcggag ccagcacctg ggcctggAAC tggccgcag cccccagctt | 5700 |
| cacccaccac ctccctacca tggacccctg caaatgtgaac gagcttcggg cctttgtgaa | 5760 |
| aatgtgtaaag caggatccga gcgttctgca caccgaggaa atgcgttcc tgagagagt | 5820 |
| ggtgagagc atgggaggta aagtaccacc tgctactcag aaggctaaat cagaagaaaa | 5880 |
| taccaaggaa gaaaaacctg atagtaagaa ggtggaggaa gacttaagg cagacgaacc | 5940 |
| atcaactgag gaaagtgtatc tagaaattga taaagaagggt gtgattgaac cagacactga | 6000 |
| tgctcctcaa gaaatggag atgaaaatgt ggagataacg gaggagatga tggatcaggc | 6060 |
| aaatgataaa aaagtggctg ctattgaatg cctaaatgtat ggtgaactcc agaaagccat | 6120 |
| tgacttattc acagatgcca tcaagctgaa tcctcgctt gccattttgt atgcaaagag | 6180 |
| ggccagtgtc ttctgtcaa tacagaagcc aaatgctgcc atccaagact gtgacagagc | 6240 |
| cattgaaata aatcctgatt cagtcagcc ttacaagtgg cgggggaaag cacacagact | 6300 |
| tctaggccac tgggaagaag cagccatga tcttgcctt gcctgtaaat tggattatga | 6360 |
| tgaagatgct agtgcaatgc tgaaagaagt tcaacctagg gcacagaaaa ttgcagaaca | 6420 |
| ttggagaaag tatgagcgaa aacatgaaga gcgagagatc aaagaaagaa tagaacgagt | 6480 |
| taagaaggct caagaagagc aggagagagc ccagagggag gaagaagcca gacgacagtc | 6540 |
| aggagctcac tatggccctt ttccaggtgg ctttcctgg ggaatgcctg gtaattttcc | 6600 |
| cggaggaatg cctggaatgg gaggggacat gcctggaatg gccggaaatgc ctggactcaa | 6660 |
| tgaaattctt agtgatccag aggctttgc agccatgcag gatccagaag ttatggtggc | 6720 |
| cttccaggat gtggctcaga acccagcaaa tatgtcaaaa taccagagca acccaaagg | 6780 |
| tatgaatctc atcagtaaat tgtcagccaa atttggagggt caagcataat gcccctctga | 6840 |
| taaataaaagc cctgctgaag gaaaagcaac ctagatcacc ttatggatgt cgcaataata | 6900 |
| caaaccaacg tacctctgac ctttcatca agagagctgg ggtgcttga agataatccc | 6960 |
| tacccctctc ccccaaattgc agctgaagca ttatcacatgt gtttgccatt agggtattca | 7020 |
| ttcagataat gtttcctac taggaattac aaactttaaa cacttttaa atcttcaaatt | 7080 |
| atttaaaaca aatttaaagg gtctgttaat tcttatattt ttctttacta atcattgtgg | 7140 |
| atttttcctt aaatttattgg gcagggata tacttattta tggaagatta ctgctctaatt | 7200 |
| ttgagtgaaa taaaagttat tagtgcgagg caaacataaa aaaaaaaaaagt ccatgttcat | 7260 |

-continued

| | |
|---|------|
| ctctaaatga catcattgtt ccaaagctt tccatttttc ttaaccttcc acctgtcaat | 7320 |
| ctataggaga tgacttctcc tacttcactc atgcattgac tccttcaatc aataaaagtg | 7380 |
| actaagaacc tgctacaggt gaggtgctgt gtttgggttt aaagtgacaa cagttatctg | 7440 |
| tcaataagcc tgacaagggtt cctatccctg tggtttgtgc actctgggtc aaactcagaa | 7500 |
| atgcaaacag gtggagagcg atgagttcta tgactggtaa agaaaaggc ctgctggtt | 7560 |
| ccctcaggat ctctgtcctt catctaaaaa tgcattttcc ttgttatcgt tccttcctt | 7620 |
| cctgtctcag aggaagacct gctcctgcta cactctgggc aaccttgc ccgtggccct | 7680 |
| gtggccccctt gggtgttcaa gtctatgtta tgccctatct tttaccctca gtcactctct | 7740 |
| ctgttaacat tctccctgtg ccctgttaacc ctccctcatc tttaaataaa tcctcctcct | 7800 |
| ttgacccctcg catgtattca gtcattgcaac tcaacaagca tttattgcac agtataattc | 7860 |
| aatttgccac ttgctaaaag tctgaacctt ggcagctgaa tgtgatcaga aaaaaagcac | 7920 |
| gactgctatg actagtctca ctttaaattc atggtcgttg accaagagct accataaat | 7980 |
| ccactacctt tctcaagttc agtcacattc ttcccttcct agatgtctgc tttctacttc | 8040 |
| tcttccttc tgaaacttcc cacaactcct cgttcattct cttctcagtt gacaactttg | 8100 |
| cttcctattt cactgaaaaa tagaagcaat cagatatgaa cttctggctg ggcattggtag | 8160 |
| ctcatgccta taatctcagc actttggag gccaaggcag gaggactgca ggttaggaat | 8220 |
| ttgagaccag cctggcaac atggtaaac tcccactgta ctaaaaattt taaaaattac | 8280 |
| tcaaacatat tggcaaacaat ctgcagttccc agctacttgg gaggttgaga tgcaaggatc | 8340 |
| acttaaacct gggaggctga ggctgcagtg agccatgatt gcaccactgc actccagctc | 8400 |
| aggcaacaga gcaagacct gtcttgagag gagaggagaa gagaggagg gggggagg | 8460 |
| caggggaggg gaggggaggg gaagggagag gggagggag aggaggagg agagggagg | 8520 |
| ggaggggagg ggaggggagg ggaggagagg agatcaggt gaggagtatg ccaaggatg | 8580 |
| ttttaagac ttactgtttt ctcttccca acaagattgt catttcctt aaaaagtatg | 8640 |
| tatcctgagg cctatattca tagcattctg aaagaaagaa aagaaaagag gaaagaaaga | 8700 |
| gagaggaagg aaggaaggag aaagagagag gaaggaagga gaaagagaga ggaaggaagg | 8760 |
| gaggaagaga agaagggagg aagaaaagaa ggaaggaagg agggaggag ggaagggagg | 8820 |
| gagggaaaga ggaagaaagg agggaaagaa ggaaggaaga gagagaggaa ggaaggagga | 8880 |
| agagagaaga aggaaggagg aagacagaga gggagtaagg aaggaaggaa ggagaaagag | 8940 |
| agaggaagga agaaatgaag gaaggaagga aagaaagaaa aaataaaaga gtgaaaacgg | 9000 |
| actggagaag aagaaaccac agttgctgct atatccacca gcctctctgc atgtcctggc | 9060 |
| ctcagccctg ctggctctg gtactgacca ctcccttcct tcctaatttc ctaattgact | 9120 |
| aggccagctg agcaggcctt ttctgtgctg aggaggtaaa tctctggata tctagactga | 9180 |
| gggggtggaaag ggccttcca gggcacacat gagacatggc agggtaggc tgctagttt | 9240 |
| attttgtttt cttttagaca cagggtcttg ctctgttaac caggctggag tgcagtggcg | 9300 |
| tgattatagc tcactgcagc cttgacctcc tgggtctccc acaatccttc cgcttcagcc | 9360 |
| tctttagtag ctggactgc aggtgcacac taccacaccc ggtccattta tttttatatt | 9420 |
| tcgttagagac aagatcttac agtttgcac agagtgtatc taaactcttg accccaagtg | 9480 |
| atcctcctgc ctggcctcc aaaagcattg ggattatagg agtgagccac tgcgtggac | 9540 |
| ctagtctgtc agctttgaag cttagatata gaaactcagag ggacttcatt tcagaggat | 9600 |
| ctgccatgtg gcccagcaga gcccattcctg aggaaatgac tggttagagtc aggagctggc | 9660 |

-continued

| | |
|---|-------|
| ttcaaagctg ccctcacttc acaccttcca gcagcccagg tgccgccatc acggggctcc | 9720 |
| cactctcaac tccgcagcct cagccccctc aatgctgagg agcagagctg gtctcctgcc | 9780 |
| ctgacagctg ccagggcacat cttgtccct caggttgac aactgggata aatgaccgg | 9840 |
| gatgaagaaa ccactggcat ccaggaacct gtcttagacc gtttgttagg ggaaatgacc | 9900 |
| tgcagggact ttccccaggg accacatcca gctttcttc gctcccaaga aaccagcagg | 9960 |
| gaaggctcag tataaatagc agccaccgct ccctggcagg c | 10001 |

<210> SEQ ID NO 13
<211> LENGTH: 10001
<212> TYPE: DNA
<213> ORGANISM: homo sapiens
<400> SEQUENCE: 13

| | |
|--|------|
| gtctgccagg gagaggtggc tgctatttat agtgagcctt gctggtctct tgggagggaa | 60 |
| gaaaagctgg atgtggtccc tggggaaagt ccctgcaggt catttccct acaaactggt | 120 |
| ctaagacaag ttcttgatg ccggtggttt cttcatcccg ggtcatttat cccagtttg | 180 |
| taacctatgg gaacaagaga ggttgctgt gccttggcaa tggacaggggt gctagatcag | 240 |
| ctctgctct cagcattggg ggaagtgcag ctgcagagat gccagtggga gccccgtgat | 300 |
| ggccgcacct gggctgctgg aaggtgtgga gtgagggcag ctcttcagcc agctcctgac | 360 |
| tataccggtc atttcctcag gatgggcctt gctggccac atggcagatg accctgactg | 420 |
| aaatccctgt gagttcatgt ctaaagctt aagcttaaa acggacagcc taccctgac | 480 |
| acatctcatg tgtgccctgg aagcttcctt ccaccctct ggatgtcctg atatttctca | 540 |
| gcacagaaaa tctctgctcc gctggcttag ccaatttggaa aatgctttt ctaagttggc | 600 |
| tcctgagcca aggacaatgt agagaggggg actttctgt gccccagcct agtccctggag | 660 |
| ccccaccttg ggagaatgag agtgtggtgc gttaaatagg cagcccagct gggacgtgc | 720 |
| ccagcatcca ggcagggaaag ggtggagag ctcttggct gctgtattat cacggaggg | 780 |
| tgcagggggc atgcagatca ctctctcatg agaacatcaa cagggtcaga ttagctctgc | 840 |
| agaggcttat ggaggagcat ggtggccaga gatgggtcag taccagagcc cagggggct | 900 |
| gaggccagga catgcagaga ggctgggtgga catagcagca actctggttt cttctctcc | 960 |
| agtccatgtt cataccctga gggctaggca tttgtataaa caaacaaaca agcaatttag | 1020 |
| aaatgggcca ggcatggtgg catgtgccta tagtcccagc tacttggag gccaaggcag | 1080 |
| gaggcctgct tgaacccaga aatttggagc cagcctggc aacacagcaa gattatctta | 1140 |
| aaaaattttt ttaatctct gagaatggg tagggccagg aagtaaagga tggccaaata | 1200 |
| ctccataagc agcaaatgcg tggctccaat gtgaacaatg atattataga ctctgttctg | 1260 |
| agacctatgc attgacacact ccacccccc cactacatct tgccacctt aaaccactga | 1320 |
| gagtggtacc tgctggatg ggtccacaca cacagtcaca catattttag gcagggtagt | 1380 |
| tgacatcccc agggaaaaag agtcacaga gagaggctga atgtttccaa ctggtagca | 1440 |
| gtaatagtac atcatgctgt acatggtaca gcacagatca ggtgaaaata atagcacatc | 1500 |
| gtgattaacc agggcttatt ccagggagtc aagaagagtt tcatatcaga aaaatctatc | 1560 |
| ttttaattc actataccag taatcaaaga aaaggattgt acatttattt tactagatgc | 1620 |
| agaaaaatgaa ttctataatt gtcaacatct actgatgata aggaaaatgt ataacaaaat | 1680 |
| aaagagacca ttctgactt gagaaggat aaataccaat atgttatagc aacagttctc | 1740 |

-continued

| | |
|--|------|
| aaactgtttt ccagggacc ctaagaatcc ctccttaggg aggcttgat ctcaaaatta | 1800 |
| tttttagaat agtgctaaca cactatttc atgtttcaagt ctcattttct catgagtaca | 1860 |
| cacaatatga caagtttagtt gatatgagtg tggatttcca catggtaact gactttcag | 1920 |
| aagctaccac ttgttgagtt tggtataata tagaatagcc acaatttatct aaaaatacca | 1980 |
| ttaaaaataca ctcccccatt tcaactatat atctgtgtga ggctgaattt tcttcatata | 2040 |
| ctccaaccta aataacatata taaaacaggt tggatgatga atcagatagg aaaatccagc | 2100 |
| tataaaaaaa aaatcagaca tgaaaaattt tcaaaagggt aaaaccatag tactcttctt | 2160 |
| acttttttc ttttggaga tggattttt tcataaaaat atattattta tgttaacata | 2220 |
| tagaagatgg ataattttt gaagaattga taaatgtta aatttttct ttcttattatg | 2280 |
| gtaaataactg atgaatagag tccccataaa taaaagttct ttgggttatt caataattt | 2340 |
| taatagtgtatc atgggatcct gagacaaaaa ggtttgagaa tcattgctct acagcaaaca | 2400 |
| ttatgtgtaa ttaagacact tcaggtgcat tctcaagaag accaataaag aggccacaat | 2460 |
| ggcaggcgtg gtggctcaca cttgttatcc aagaacttag agaggacgag gcaggtggat | 2520 |
| cactggaggt caggaattct caaccagcct ggccaacatg gtgaaaccct gtctctacta | 2580 |
| aaagtacaaa aattagtcgg gtgttagtggc aggtacctgt aatcccaagt acttgggggg | 2640 |
| ttgaggcagg agaattcactt gaagccggga ggtggaggct gcagtgagcc gagatcgtgc | 2700 |
| cactgcactc cagcctggc aacggagtga gacttcatca tggaaaaaaa aacaaagagg | 2760 |
| ccaggatgtc tggttgttac tgccactgtt tcacatatcc ctgaaggacc tgcccaatgc | 2820 |
| taaagaaaca caaggaaggt aagaggtgaa agagaagaaa taaaactatc attgtttgaa | 2880 |
| gatgacacca tcttttacat agaaaacctg tttagaatcaa atggcaagct attagaacta | 2940 |
| ctaagagaat tcagtgaggc tgctgtattc atggcaaaat tttaacaatt gatagcatt | 3000 |
| ctctgcaaca ttcccttaata gttataaaaat acagcacaaa gtagtaccaa aaatattaac | 3060 |
| tatctaggaa ataaccttctt acagagaaaaa ttttagtctgt taaaggataa acagtggcaa | 3120 |
| tgtacgtcat gtccacagag attatatttt agcttagcaa agataccat tctcccaaatt | 3180 |
| ttatTTATAA attaaatgca atgtgaatca aaatttcccctt ctggatTTT tatcaggaag | 3240 |
| gcaacaaatt ctttctttct ttctttcttt ctttctttat ttatTTTTT atttattttat | 3300 |
| ttatTTTTT ctttccTTCC ttccTTCCttt ctttccTTCC tttctttttt tctttctttc | 3360 |
| tttctttctt tctttcttc tctttttctc tctccccccc tctctcttc tctgtcttc | 3420 |
| tctctcttc tttctttctt tctttttttt agacaaagtc tggctctgtc | 3480 |
| acccaggctg cagtgcagtg atacaatctc agctcaactga aacctcaacc tctccggcat | 3540 |
| caggtgaacc tcccacctca gccccccgag tagctggac tacaggtgca caccactgg | 3600 |
| cctagataac tttttgtatt tattgtaaat aaacacaaaa aataaatatt ttgctcagg | 3660 |
| tggctggaa ctccctggct caagcaatcc gcctgccttgc gcctccaaa gtgctagaat | 3720 |
| tacagttgtg agccaccaca cccagccaat aaattaattc tttatgtatca ataagttatc | 3780 |
| tatgaaaatt aagtcaagctg ggtgcgggtgg ctcacgcctg taatcccagc actttgcgg | 3840 |
| gctgaagcag gtggatcacc tgaggttggg agttcaagac cagccggacc aacatagaga | 3900 |
| aaacccgtct ctactaaaaa tgcaaaaatta gctgggtgtg gtggcatatg cctgtatcc | 3960 |
| cagataacttta ggaggctgag gcaggagaat tgcttgaacc cggcggtgg aggttgcgg | 4020 |
| gagccaagat tgcaccattt cactccagcc tggccacaa gagcggaaact ccatctcaa | 4080 |
| aaaaaaaaaaa gagaagttaa gtcaatgaaa agttaagtca attaaaaaaag taagagctgt | 4140 |

-continued

| | |
|---|------|
| agtgtttaga tatatacaca cacacatata tataattta tctttatata tgtatatata | 4200 |
| tctttcctt ttttgagac cgagtctgtt tttgttgcgc aggctggaa gcagtggcgc | 4260 |
| gatctctgt tactgcaacc tctgcctccc aggttcaagc gattctcgta cctcagcc | 4320 |
| ccgagtagct gggattacag gtgcctgcgc ccatgcccg ctaattttg cattttgt | 4380 |
| agagacgggg tttcaccatg ttggccaggc tggctcaaa ctcctgaccc caggtgatcc | 4440 |
| accggcctca gcctccaaa gtgctggat tacaggtgtg agccaccgcg cccagccata | 4500 |
| tatttgctt ttcatctgca gctcctggat cctaactcct tgttatattg ttggcactt | 4560 |
| taggcctcag taaacagaat ctctgtctat gaccttctcc tgtccttctt ccacctgccc | 4620 |
| aaagcaggac tctaatttga ttgtgggtca aaagactctc attccagaaa gggccttgcc | 4680 |
| tcatacccta gaggaaggaa tgctgcacag aaacgccaag tctgaacaga caagccttgc | 4740 |
| tgggttata ccatatgctt tttgtccaat cacatttctt catggttgc aatcatgct | 4800 |
| atgtaatgaa gcctccataa gaacccagaa ggacagggtt cagagagttt ccacatagct | 4860 |
| gaacactatc tggagagtga acacttcata gagagtggca caccagaga gatcatgaaa | 4920 |
| gctccacgcc ccttccctt tacctcgccc tccacatctc ttcatctgta tcttcataa | 4980 |
| tatccttat aaataaacca gcaaatgtgt ttccctgagt tatgtgagtc actctagcaa | 5040 |
| attaatcgaa cccaaagagg gggcatggg aaccccaact tgaagccagt cagtcagaag | 5100 |
| ttccagaggc ccagacttgc aactggggag aaagaggggg aggtcttggg gactgagccc | 5160 |
| ccaacctgtg gnatctgaca ctgtctccag gtaggttagt ttggaaactgc attggaggac | 5220 |
| actcctggtg tctgctgctt ggtgtgtggg gggaaaaacc cacaccttgc gttacggagg | 5280 |
| tcttctgtgt tgacgatcat tgctgttga gggcagaggg aatacacggt ttgagagagt | 5340 |
| ttttccctga catgagcga cagggacat gtactggct ctgagatggg ggatcatggg | 5400 |
| atctgccaca agtggggaga ccactgtgac ccctgccaca gtcttgggg cagagggtgt | 5460 |
| ctcgccccca gaagaagcga gagttgtttg cagtagcgt tatgtccaaa gtggcgcca | 5520 |
| ggaaagttagg gctgccacgc tttgaagac tccttactc ccagcctgaa tgaaaccatt | 5580 |
| tcctgtaaag cgctaagcat aaagtttgc aatggtgatc cacggagaag tgagtgtacc | 5640 |
| ccaccccgcc atcccacagg gaatgtcgaa gtgatgttgc tctgcaccta gggaggaat | 5700 |
| ggttcatgag atgtggtgaa gatgttgagg gcccgtggac atcagatcct accctacctg | 5760 |
| tgccaggaca agccatgcgc atgtgcttca gaccaccagg caacaggagt gttgcatgag | 5820 |
| gtgtgaagca ggcacctggg aaagaggagt gtgaacagca gatggacac actggggca | 5880 |
| gtcataggaa tgaaatgtcc caggatggat gcaggcaggt tatggaggac ttagtgagga | 5940 |
| ctgctctctt ggtggaaatt gtggagtgaa agactggatc gagactggag gtgttttaag | 6000 |
| taggaaagcc aacttgcaag ggtgaccagg gaaactatgt cggccaagg tgagacatgc | 6060 |
| actggcaaga ctctcagaca gcctggctt tctaagcaga atgcttgagc catgccaacg | 6120 |
| gtgcctcgca agttgttatta atcatgtctt ttcattttgt gttttgggtt cttggcatct | 6180 |
| ggcccttgc tgaccctaa ggaccatttc tctcagagct agtcaagtcc tagacacagt | 6240 |
| aaatgactct cctggggagca tgccttccat gtgcagacca accaatcaag agtccacact | 6300 |
| cccacccacc tcctttatcg agctctcaca tcctggggca ccatccaccc gcccataatca | 6360 |
| ctcaaggacc acgtccccaaa caacttaggaa cagcctccat gcccctgcac ccattgaaat | 6420 |
| tattcatgct agccaatcct aaacctgtgt atgctgccac accattcctt cctgcagaaa | 6480 |

-continued

| | |
|--|------|
| cacagtaagg actcttccta cacccccc acttcctctg ctccctgact tacccactta | 6540 |
| cttcctggtg cagtccccctg tggcatagtt cactcttcc ttggggaaac tgtgaggcta | 6600 |
| tcttctcaat ggcagtcatac tcctgagctg ttggccttgc catacctaac taataataaa | 6660 |
| atctatattc taaggtaaaa acaaaaacaga tagggctctca ctctgtgcc caggctggag | 6720 |
| tacagtggtg tgatcatgac tcactgcagc ctcaaactcc tgggctcaag cagttctc | 6780 |
| atctcaacct cccgagtagc tgggactaca ggcacacacc accatgcctg gctagtttc | 6840 |
| ttatTTTT ttagataaca gggcttggtt atgttgccaa ggctggtctt gaactcctgg | 6900 |
| gctcaagtga tcctcctgcc ttggcctccc aaactgctgc aattacaggc atgagccacc | 6960 |
| atgcccagat cagaaatctt actaaaaata tttcaaggag aagagaaagc caaagatgtt | 7020 |
| gaatatatat atatgtgtgt gtgtgtgtgt gtatatatat gtatatatgt gtatatatgt | 7080 |
| gtgtatatat atatgtatat atgtatatat atatgtatat atgtatatat atatgtatat | 7140 |
| tggggcagggc gtgggtggc tcactgtgg tccttaactac ttgagagtct gaggtggag | 7200 |
| gattgcttga gcctgggaga tcgaggctgc tgtgagctga gactacacca ctgcactcca | 7260 |
| gcttgggtga cagagtgaga ccctgtctcc aaaaaaacaa aaagaaaaag aaaaaaagat | 7320 |
| ggaaaaagac atgaaaaaac aacaacagaa atacccacac atcatcaatg ggagggaagc | 7380 |
| atcttggggc agcaaagcgg gagtgctagt agagaggcag atagggcggt ggacctgagg | 7440 |
| cattaaggaa agtcaggatt tggagcttac aagtctctca ttggagatgg gatggggtg | 7500 |
| gaatgaatgt ctgagcaaac acaaagcatt tccttccta atgactcccc accagtctaa | 7560 |
| agaatcccac attaggtcga acacgggtggc tcacgcctgt aatcccagca ctggggagg | 7620 |
| ccaaggcggg tggatcacga ggtcaggaga tcgagaccat cttggctaac atggtaaac | 7680 |
| cccgctctca ctaaaaatac aaaaaaatta gccggggcgc atggggcgc cctgttagtcc | 7740 |
| cagctactcg ggaggctgag gcaggagaat ggtgtgaacc cgggaggcag aacttgcagt | 7800 |
| gagcctagat cgcccccactg cactccagcc tgggggacaa aacgagactc tgtctaaaa | 7860 |
| aaaaaaaaaa aaattccac attagagttt gggaaatggg cagtcctggt ggaagttagg | 7920 |
| gaacagatct gggacacgtt atagccagct ggactacagg aggcataag ctcaattctt | 7980 |
| ccttgactct gaaacccccc actggcccta atgccttagta attccaggcc ttcccagg | 8040 |
| gtgccaggct tggaggtgaa cacatctatg tgccaaagaag gaaaggtatg ccaagcagg | 8100 |
| gcttaagtca tccttatcct cagtcgtct atgagtggta tgtacccctg ttccccttg | 8160 |
| aagatctgct gggcttaggt ctccctggctg tgagttcccc atacctgggc ataaatgtag | 8220 |
| tgagcctgag ctcccaaata aggtgggggg ctccagagag gtggagagcc ctgtgtctgg | 8280 |
| gaagtgtgcc cacccacgag gtctgaccag gaagatacac tgctagggtt atggaaaaag | 8340 |
| actatgtgtc aaggctcttt gattctccat ctggcagag aatcatctt aattaatgg | 8400 |
| aaactggaag gcaaattact tggacctgaa attactttt gtttattgaa ccactgtgtt | 8460 |
| gtaaatcaca tctctctgaa ggcaagagaa atcagggagt tacaaaatgt ttaggagaac | 8520 |
| taaacaggac tcctgtttt gctaactaat cagattgaga caggctctc ggtaaatcta | 8580 |
| caaatttgc gttgttcaac cataaggact aaatttccta tgctggattt tcctgacaat | 8640 |
| gaatgtaaaa gggaaaggag tcttttgac aaaatattt attgttcatc taaactgaaa | 8700 |
| aacttctcta tttttcaaaa ttgttatacg tggtaaaga tgttagatatt tgaatagcct | 8760 |
| aactggtaca gaaggtttaa tgatgattcc taagacatac ctataaatta cttgaaattg | 8820 |
| aaacgaaatt taagaagaat tattgaaatt ttccccttct caaatgagtt cttagttca | 8880 |

-continued

| | |
|--|-------|
| taaatactat acaagtccat aagagatttg gggtttttag atgtctttt ttttttttt | 8940 |
| ttttcagacg gagtttcaact gttgtgcct aggctggagt gcaatggcgt gacctcagct | 9000 |
| cactacaacc tccacacctcc aggttcaagc gattttcctg cctcaggcctc ccaagtagct | 9060 |
| gggattacag ggacacctgcca caacgccaag ctaatgtttt gtatttttag tagagatggg | 9120 |
| gttcaccatg ttggccaggc ttgtctggaa ctccctgaccc caggtgatcc acccgccat | 9180 |
| aatttattac tcccttttgc aaatgtttga aaaggaataa agtgcataat ttttaaacag | 9240 |
| aatgcagagt tctgttgtcc tttggcaata ccagttcag actctgagag tggctttgc | 9300 |
| tgttgccgac agtgggctga tgaccaaata ccaacatgcc cccgctgcga gtccttcata | 9360 |
| acctgattca gtcatactt agaggccagc aggcttcagg gaggcgtgag cctcagccaa | 9420 |
| caacctatacg gggaaagagac gcagaactca atgcagacag gtttggattc tggccttag | 9480 |
| agaatgcaac ttggaaactc tgagccagga gaaaagggtt ctctctccat gagagagtg | 9540 |
| gggctttgtg agaagcgaca cacagcaaac acaattaaga gtccacccct cagcggggcg | 9600 |
| caggggctca cgcctgtaat cccagcaattt tgggaggccg aggccgggtgg atcacgaggt | 9660 |
| caggagatca agaccatcct ggctaacaca gtgaaaccct gtctctacta aaaataaaaa | 9720 |
| aaaatttagcc gggcgtggtg gcggggcgccgt gtggtcccag ctactcggga ggctgaggca | 9780 |
| ggagaatgggt gtgaacccgg gaggtggagc ttgcagttag ccgagatcgc gccactgcac | 9840 |
| tccagcctgg ggcacagagc gagactccat ctcaaaaaaa aaaagaaaaa gaaaaagaaa | 9900 |
| aagagtccgc ccctgaatta aatagtttgtt cctttgtgt tcctggat tcacttgcta | 9960 |
| agtggaaagaa acaggaggaa atctttctc ctgcctcct g | 10001 |

<210> SEQ ID NO 14
<211> LENGTH: 1209
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 14

| | |
|---|-----|
| cagggctggg cggcggcgcc ggcggcggtc atggAACGCC aagaggagtc tctgtcccg | 60 |
| cggccggccc tggagaccga ggggctgcgc ttccctgcaca ccacgggtggg ctccctgc | 120 |
| gccacctatg gctggtacat cgtttcagc tgcataccctc tctacgtggt ctttcagaag | 180 |
| ctttccggcc ggctaaagagc cttgaggcag aggcatgtgg acccgactgc ggctgctgt | 240 |
| gaacctgatg ttgttgttac acgacaagaa gcttttagcag ctgctcgact gaaaatgcaa | 300 |
| gaagaactaa atgcgcaagt tgaaaagcat aaggaaaaac tgaacaact tgaagaagaa | 360 |
| aaaaggagac agaagattga aatgtggac agcatgcaag aagggaaaaag ttacaaagga | 420 |
| aatgcaaaga agccccagga ggaagacagt cctggccctt ccacttcatac tgtcctgaaa | 480 |
| cggaaatcgg acagaaagcc tttgcggggaa ggagggtata acccggtgtc tggtaagga | 540 |
| ggcggacttg ctccctggaga cctggacgc gaggccccgtc atctggcggta tgaggctaag | 600 |
| aatcttgttacgtgtcacttt tgacattagc aagatgaacc cttaaccctc gattcaattg | 660 |
| ccttacgcac gcttttccaca gtgacttagcc aaggggaggt ggggttgatt tctgttccta | 720 |
| actacacccctg catatgtcag ggctccagtc agcaaaaggt atagatgttg cctctaggca | 780 |
| tgaggtcatt ggtcacattc tacttggaga cagtgattgc attcattgat ttcatggta | 840 |
| attgcttagtt ggttaggtaaa ggcctctaga tgattagcaa tcttgataaa agaggcctag | 900 |
| taatgttctt ttgaggttag aaatccctgc tgcttaggaca gtctctgtga caggttgcgt | 960 |

-continued

| | |
|--|------|
| tgaatgatgt cttccttatac aatggtgagc ccaccagtga ggattactga tgtggacagt | 1020 |
| tgtggggtt tggggatgtt tatttttttt tatgtacaga actttgtaaa aacgaaacta | 1080 |
| tttaaaaaac aagaataaca ttttagcat cttaattcaa ggagatttat ggacttcaat | 1140 |
| ttgtctatca aacattaaat agcttttat tacaacctcc aaaaaaaaaa aaaaaaaaaa | 1200 |
| aaaaaaaaaa | 1209 |

<210> SEQ ID NO 15
<211> LENGTH: 204
<212> TYPE: PRT
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 15

| | | | |
|---|---|----|----|
| Met Glu Arg Gln Glu Glu Ser Leu Ser Ala Arg Pro Ala Leu Glu Thr | | | |
| 1 | 5 | 10 | 15 |

| | | |
|---|----|----|
| Glu Gly Leu Arg Phe Leu His Thr Thr Val Gly Ser Leu Leu Ala Thr | | |
| 20 | 25 | 30 |

| | | |
|---|----|----|
| Tyr Gly Trp Tyr Ile Val Phe Ser Cys Ile Leu Leu Tyr Val Val Phe | | |
| 35 | 40 | 45 |

| | | |
|---|----|----|
| Gln Lys Leu Ser Ala Arg Leu Arg Ala Leu Arg Gln Arg Gln Leu Asp | | |
| 50 | 55 | 60 |

| | | | |
|---|----|----|----|
| Arg Ala Ala Ala Ala Val Glu Pro Asp Val Val Val Lys Arg Gln Glu | | | |
| 65 | 70 | 75 | 80 |

| | | |
|---|----|----|
| Ala Leu Ala Ala Ala Arg Leu Lys Met Gln Glu Glu Leu Asn Ala Gln | | |
| 85 | 90 | 95 |

| | | |
|---|-----|-----|
| Val Glu Lys His Lys Glu Lys Leu Lys Gln Leu Glu Glu Lys Arg | | |
| 100 | 105 | 110 |

| | | |
|---|-----|-----|
| Arg Gln Lys Ile Glu Met Trp Asp Ser Met Gln Glu Gly Lys Ser Tyr | | |
| 115 | 120 | 125 |

| | | |
|---|-----|-----|
| Lys Gly Asn Ala Lys Lys Pro Gln Glu Glu Asp Ser Pro Gly Pro Ser | | |
| 130 | 135 | 140 |

| | | | |
|---|-----|-----|-----|
| Thr Ser Ser Val Leu Lys Arg Lys Ser Asp Arg Lys Pro Leu Arg Gly | | | |
| 145 | 150 | 155 | 160 |

| | | |
|---|-----|-----|
| Gly Gly Tyr Asn Pro Leu Ser Gly Glu Gly Gly Leu Ala Pro Gly | | |
| 165 | 170 | 175 |

| | | |
|---|-----|-----|
| Asp Leu Asp Ala Glu Ala Arg His Leu Ala Asp Glu Ala Lys Asn Leu | | |
| 180 | 185 | 190 |

| | |
|---|-----|
| Val Ser Val Thr Phe Asp Ile Ser Lys Met Asn Pro | |
| 195 | 200 |

<210> SEQ ID NO 16
<211> LENGTH: 10907
<212> TYPE: DNA
<213> ORGANISM: homo sapiens

<400> SEQUENCE: 16

| | |
|--|-----|
| tgagcagcct gagatgtcag taattgttagc tgctccaagc ctgggttctg ttttttagtg | 60 |
| ggatttctgt tcagatgaac aatccatcct ctgcaatttt taaaagcaa aactgcaaat | 120 |
| gtttcaggca cagaaaggag gcaaagggtga agtccagggg aggtcagggg tgtgaggtag | 180 |
| atgggagcgg atagacacat cactcatttc tgtgtctgtc agaagaacca gtagacactt | 240 |
| ccagaattgt cctttattta tgtcatctcc ataaaccatc tgcaaatgag gtttatttgg | 300 |
| cattttgtc attttggagc cacagaaata aaggatgaca agcagagagc cccgggcagg | 360 |
| aggcaaaagt cctgtgttcc aactatagtc atttcttgc tgcatgatct gagtttaggtc | 420 |

-continued

| | |
|---|------|
| accagacttc tctgagcccc agttcccca gcagtgtata cgggctatgt ggggagtatt | 480 |
| caggagacag acaactcaact cgtaaatcc tccccttct ggccaacaaa gctgctgcaa | 540 |
| ccacagggat ttcttctgtt caggtgagtg tagggtagtgg ggagattgg tcaatgtcca | 600 |
| attcttctgt ttccctggag atcagggtgc cctttttgg tagtctctcc aattccctcc | 660 |
| ttcccgaaag catgtgacaa tcaacaactt tgtatactta agttcagtgg acctcaattt | 720 |
| cctcatctgt gaaataaaacg ggactgaaaa atcattctgg cctcaagatg ctttgggg | 780 |
| gtgtcttaggt gctccaggtg cttctggag aggtgaccta gtgagggatc agtggaaata | 840 |
| gaggtgatat tgtggggctt ttctggaaat tgcagagagg tgcacgttt ttataattta | 900 |
| tgaatttta tgtattaatg tcatcccttca gatctttca gctcattgg gtaaattcctt | 960 |
| gcctgccaga gtgggtcagc ggtgagccag aaagggggct cattctaaca gtgctgtgc | 1020 |
| ctcctggaga gtgccaactc attctccaag taaaaaaaaacg cagatttgtg gctcacttcg | 1080 |
| tggggaaatg tgtccagcgc accaacgcag gcgaggact gggggaggag ggaagtgc | 1140 |
| tcctgcagca cgcgaggttc cgggaccggc tggcctgctg gaactcggcc aggctcagct | 1200 |
| ggctcggcgc tgggcagcca ggagcctggg ccccgggag ggcggtccc ggcggcgc | 1260 |
| tggcccgagc gcggtcccc cctccttgc gcgcccccgg gcgccgggt tgtatatcag | 1320 |
| ggccgcgctg agctgcgcca gctgaggtgt gagcagctgc cgaagtca gtcgtgttgc | 1380 |
| gccggagctg ggccgcggatt cgccgaggca ccgaggcaact cagaggaggt gagagagcgg | 1440 |
| cggcagacaa caggggaccc cgggcccggc gcccagagcc gagccaagcg tgccgcgt | 1500 |
| tgtccctgcg tgtcccgag gatgcgtttt cgcgggtgt tgctgcgttc acaggtgttt | 1560 |
| ctgcggcagg tgaatgcgg gcgtgggtcg gtgcgcgcggc ggcttgcgc cacgggtct | 1620 |
| ctataagtgc gcggtgacg agagtccggta tgtgcggag accccggggc ggagagcgg | 1680 |
| attacaagta caggaatccc tggcacgt ccccgccccct ggaaacccag ctggggcgg | 1740 |
| ggagggcgtg gacgggaccc ttctggagc tcgccttgg ctgcgggtgg ctccaggccc | 1800 |
| caggcgcagt ttgcgcggc cgtggggatg aagtccgtgt ccctggaggg gcccaggaag | 1860 |
| ggcgaggaaa gcgagtgga gtaagttcgt ctaggatcg tcccggtgg ctctggatc | 1920 |
| caatctgcgc cgcctggcc caggtcccag gttcagggtcc tttacgcac tgcgtccacc | 1980 |
| acctggctga ggcgtgaggt cagcgcggc tggccctgg ccctggaaat tgcgcggaa | 2040 |
| cccgccccct aaggactagc gaggaggtga ctcactgtga caaggagacc ccaggaaacg | 2100 |
| gactgtatga ggtcagaacc cgcgggggaa tggggtacag cgggactcca gaagccctct | 2160 |
| ccctgcggcc ttgcgggtct ccgtccccc atcggcacag tgacctattt ggctggaaaca | 2220 |
| gtttgttccc aagggaaaccc ggcactggag gtccgggaca ccgcgtcgaa tccccgtcc | 2280 |
| gcggcgcgt gttaggggtcg gggagtcacg gcccgcgt gggccggctc taaccagcct | 2340 |
| gtcagtgcgg gaaggggcaag ggttcctct acctttcc caccgcggcc gggagaatcg | 2400 |
| cggcccgacc tgcctcggtt cggggggcgt ggactccggg gcgggagcgg agcccacgcc | 2460 |
| tggatggag gcgccccggg ttcatgtttt tgaggggtgg ggggtctggg gggcagcagc | 2520 |
| ctgctcaggc cctctatcag ctgcctcggtt ggctcaggcc ttcccgaccc agcccagatt | 2580 |
| ccctctccga aagctacagg gctgagcggc gcaggggggc gagtcggccc ctggggcgc | 2640 |
| gccgcctggc gcggaccaca gcgcgtccctc tccgtcccaa accccctgggg gacacttgcg | 2700 |
| ccctttcgt gaggaaaacg atcttggagc tgggttagga acttggggcg cccaggcagc | 2760 |
| ttccctctc cttgcctccc tccacgtcgc gtttctggga ggacttgcga gcggttttgt | 2820 |

- continued

tttcgttgc cccgtctatt tttatcc agggatctga ctcatcccgt gctttggcg 2880
tggagataag gtggaggggc cggctcccg cgccgcgcgc cgtgcgtgtc tgccgcggcg 2940
tgtgtgtgtg tgtgtgtgtg tgtgtgtgtg tgtgtgtctg tgtcagagac ggcacaagag 3000
cgccgcggttt cccaacagcg gcgggagttt cgaaagcctg gccggctcag cgtgacgtgt 3060
tcgcggcccc ccggtccctt cccattctcc ccctccccac cccagggtga cgccgcagccg 3120
gagtggaaagc agagtttgg cggcgagca gcgccttgc ggaaactgac tcatactac 3180
tccctccagc ggtccgaggc tctgcccacg cacctccac tccgcgcgtg atttcctgga 3240
ggccggcgcc ccctcccgcc cctggcgga atagcacaca ggctttcccg cggagtgggg 3300
ctggccggcg cgaaccgccc cggctactcc tggctcatc cgagatcaac ccctatgcc 3360
ttaccacccc ttcaaaggag cactccttag gttcaacagt attcaactgag ctcttactgg 3420
aaataaaaat atggctgaag tctaaggcag gaaggccaat aaaggaggct atttttaatt 3480
gtttctaaaa caagggttg cgtttctgag tttctttgg gctgaaagtt attatgagca 3540
tgagagcaga tttgtatggg ggaggagagg cctatgagag ccataagaga aggagggtg 3600
gtagaagagg agagggtgcc tgcctagatc ctagtcctgt cttgaactcc cgagagccag 3660
ggaatatcca gtccttgat gaagccctag gcggggcgct ctccttgatg cctatgatgt 3720
attgagaccc agaatgtcca tttcaaacat accagtgtgt ctccgcttgg ctggcacc 3780
aagagtgccc atctgaggaa ttgtgccaaa cacttgcttgc aatcttcaat ttggattaag 3840
ttggtctcg gaggcaggc ctcagcaatc tatattttga aaaaactccc tagtgcttt 3900
tctttcttc tttctttctt tctttcttc tttctttctt tctttcttc tttctttctt 3960
tctttctttt tctttcttc tttcttttc tttctttctt ttctttctt ctttctttctt 4020
ttctttctt ctttctttct tcctttctt ttctttctt ctttctttctt ctctctttctt 4080
ttctttctt tcgacagagt tgcactctgt cacccaggt ggagtgaat ggcaccatcc 4140
tggactcaag tagtcctcct gtttcagcct cccaaatgaa cgggaccaca ggcgtgatcc 4200
ccccgcggcc atgcccagat ttttttttt ttttttttt ttttgagatg cggtctcgct 4260
ctgtcacccca ggctggagtg cagtggcggt atctcggctc actgcaagct ccgcctcccg 4320
ggttcacgcc attctcctgc ctcagcctcc cgagtagctg ggactacagg tgctgccatc 4380
atgcccggct aattttttt tgtatttta gtagagacgg gggtttacc gtgttagcca 4440
ggatggtctc aatctcctga ctcgtgctc cgcctcctc ggctccaa agtgctggga 4500
ttacaggtgt gagacactgc acccaaccac ccagctaatt tttattttt tttatTTTA 4560
gttagagacag ggtctcagct agttgcccag gctagtcttgc gacccttggg ctcaaattgt 4620
tctccacccct ctgcctccca gagtattagg attacaggca taagccactg cccctggcct 4680
ccccaaatgtaa ttgtgtatggg cctctctgtt taagaaacct caaaattaga gagggagtg 4740
ggttcaatac tacagcacag gactcaggc aaacaggcct gggttcagat cctggctgtg 4800
ccacttatga actgtgtgtat gttaggcaag ttacttaact tatctgagcc ttgggtgcct 4860
cttctgtaaa aagggagcta atagatatcc actttttagg aggattgata tttttaact 4920
gcttagaaca gcccccAAAC ataaaaatataaataat cccaaatcat gccttagcaga 4980
gggtggatag aggttatttg agggctctgt ccactgtact gggtgacc 4980
ttttatggggcctt ggcctttta gctgtatgac tcaggggcaa gtctcatatc tcttccatct 5040
cctggccctt aaacttggtg tgaagttacc aagagcctcc tctcccaacc agctgggacg 5100
cctggccctt aaacttggtg tgaagttacc aagagcctcc tctcccaacc agctgggacg 5160

-continued

| | |
|--|------|
| tgaaaactgtg ggctccactg atcacaagca gtggggtgag gtggggtgga gcagatgtgg | 5220 |
| catgtgtccc gggcttcctg cctcatgagg actcagcaga gcttcaccc ccagaaactg | 5280 |
| caagttggga cttgtcccta ggaaaatcca gttgctgcc aagtcgtgca gtcactcagc | 5340 |
| cctggagtca agccagagca ggcaggtagg tgccagggt ccctcatggg caaactcact | 5400 |
| ctccgttttc cctctcctga agggggagga gaggagccag gtagaccagc caccttaat | 5460 |
| tttcttttg cctgcaaaac ggttccttg gacacaggca acacaggca ggggctgcca | 5520 |
| ggtgtctaga cttcagatca cctgatgtgc ctggcaggat gtggctcagc ctggagaaa | 5580 |
| tcatcccttg cgctgccccg cccggccctt ccttacccct aggccacccg cctgacgaca | 5640 |
| tccttggaa aggcctcag cctacagcac ctgtcagctg ctgtctgaag gagtagttg | 5700 |
| gcagggggaa gtgatagggg ggaggctcg taaaactgaa ggcagagagg aataatcata | 5760 |
| cttctgtttt caatgcactt ctctatacga agtgctgctg gcacgttacc tacattaact | 5820 |
| cagttattc tcatgtctat cctctgagac agtcactatt actatcccc ttttatagat | 5880 |
| gaggaaacta gagctcagac aagttaagtt gcttgcacag ggtcacctag taaaacctgg | 5940 |
| actccagccc aggtgatctg gctccagagc cctcctgctt aaccaccagg atacagcctt | 6000 |
| tcattcagct ctgttctgctc tgccttgctg catggactct gtgatcaatt tcttgagtat | 6060 |
| gtgtctgttag ccatgctctt taaacttcta catggccca tttatggatg aggaaactga | 6120 |
| gacctagaga cattaagtgg ctttttaaag cttacgtagt aactggcaga gctaggacca | 6180 |
| caacccgggt gcttttgcc ccaaagtccc gggtaacttt acttggcaga gcagggttac | 6240 |
| cctacttggg gatctggcgc ggggactta ggaggctgga ggaactgtca gactgtttct | 6300 |
| tcttttggga attgaccttc tggccagggc tgcgattagg aaactgctgg actctggcaa | 6360 |
| ttcacacata tttggggggc attcacaccc atgagggaca cctctgggg gaaaacaaat | 6420 |
| tgatttttagc tgataataacc tggtaaaaa caggaccctg gtccttgctc ttgcaataga | 6480 |
| cttgcccttg ttgacattag cttgcccctc agttgcctgc tctccagtg accttggtgt | 6540 |
| gccaggctgg ctgagctctg ctggggggg tcaggcctcc tgtggaaagg aagcaggaag | 6600 |
| accagctgga aggagtgaga gagaccctct ggttaggaaga cgtcacctga ggtgacacag | 6660 |
| caaagcccg ccaggttaaca tagtgtctaa tctccgcgt gaccaggccc ttccctgtat | 6720 |
| ctctgctgca ggcccattgt cagaacccgc tggggatgtc cgtcagaacc catgcggcag | 6780 |
| caaggcctgc cgccgcctct tcggccctgt ggacagcggag cagctgagcc gcgactgtga | 6840 |
| tgcgctaattg gccccgtgca tccaggaggc ccgtgagcga tggaacttgc actttgtcac | 6900 |
| cgagacacca ctggagggtg acttcgcctg ggagcgtgtg cggggccttg gcctgccc | 6960 |
| gctctaccc cccacggggc cccggcggagg cccggatgag ttggggaggag gcaggcggcc | 7020 |
| tggcacctca cctgctctgc tgcaggggac agcagaggaa gaccatgtgg acctgtcact | 7080 |
| gtcttgcattc cttgtgcctc gtcaggggaa gcaggctgaa gggccccag gtggacctgg | 7140 |
| agactctcag ggtcgaaaac ggcggcagac cagcatgaca ggtgcggaca tgtgcacgga | 7200 |
| aggactttgt aagggaccag gattctcaga atccatggtc caagggctga cctgtcttgt | 7260 |
| cctggtccag catgctccag gtagaaggaa acaggcccag agaggggaag caacccct | 7320 |
| gaggtcacac agcaagtagg cagcaaagac caactagta acatttattt ggaatgtca | 7380 |
| ttatgccagg ccctttgcca agcttctaag gtatgtttat ttatgcctta tagcaatgtt | 7440 |
| ataacataag acattttgtt caccctgccc gccttcttt ttgagacagg tgtcttaact | 7500 |
| ctgttggcca gactggagtg cagtgatacg atcatggctc actgcagctt caaactcctg | 7560 |

-continued

| | |
|---|------|
| ggctcaagcg atcttcctac ctcagcctcc tgggttagctg ggaagctggg actatacggt | 7620 |
| tacaccacta cgccccggta attttttagt tttttgtaga gacaaggctc caccatgtt | 7680 |
| cccgggctgg tcttgaactc ctgagctcaa gcagtccccc tgcctcagcc tcccaaagt | 7740 |
| tttgtgattac aggcgtgagc caccatgccc agcccccattgc catccttta gggcaaggaa | 7800 |
| accaggctca gagaggtaga gtgatttatac taaggtctca aagtgaattt gccgttgggt | 7860 |
| caagactaat tataataaca acaactactg acgtttatat gggcccgca ttgtgctgaa | 7920 |
| cactttcatg gatTTTgttaa cagaatccct agatcagcac tgtcagtaa ctctgcagg | 7980 |
| atgggagtgt ccggtacagg ggccacgagc cacatacggc tgggtgtcat ttgacacaca | 8040 |
| gctcatgtga ctgaggaact gaattgttca ttttatttga ttgtgtctg tttaaacaag | 8100 |
| cacacagagc tagtagtggt tcctctgctg ggcagcttga ctttagagcag acccatgggt | 8160 |
| gcgggtgcgg tgatggataa aatcacatct gtgaagcatg gtggacact ccataatacc | 8220 |
| cctcaagaga cagagtggac gttccccgag ttcttcctgt tctcagcagt cggccccatt | 8280 |
| ggccccaggg aagggtgtcc tggcccccca ctgtcttctt cagttggca gtcggccgc | 8340 |
| gtctcttctt tcttggcctg gctgacttct gctgtctctc ctcagatttc taccactcca | 8400 |
| aacgcggct gatcttctcc aagaggaagc cctaattccgc ccacaggaag cctgcagtc | 8460 |
| tggaagcgcg agggcctcaa aggccccgtc tacatcttct gccttagtct cagttgtgt | 8520 |
| gtcttaatta ttatTTgtt tttatTTaa acacctcctc atgtacatac cctggccgc | 8580 |
| ccctgcccc cagcctctgg cattagaatt atttaaaca aaactaggcg gttgaatgag | 8640 |
| aggttcctaa gagtgctggg cattttattt ttatgaaata ctatTTaaag cctcctcatc | 8700 |
| ccgtgttctc ctTTTcttctt ctcccgagg ttgggtgggc cggcttcatg ccagctactt | 8760 |
| cctccccc acTTgtccgc tgggtggtaa cctctggagg ggtgtggctc cttccatcg | 8820 |
| ctgtcacagg cggttatgaa attcaccccc ttccctggac actcagacct gaatttttt | 8880 |
| tcatttgaga agtaaacaga tggcaTTTG aaggggcctc accgagtggg ggcacatca | 8940 |
| aaaactttgg agtccccctca cctcctctaa ggtggggcag ggtgaccctg aagtgagcac | 9000 |
| agcctagggc tgagctgggg acctggtaacc ctcctggctc ttgatacccc cctctgtctt | 9060 |
| gtgaaggcag ggggaagggtg gggTctgga gcagaccacc ccgcctgccc tcatggcccc | 9120 |
| tctgacctgc actggggagc ccgtctcagt gttgagcctt ttccctcttt ggctccctg | 9180 |
| tacctttga ggagccccag ctacccctct tctccagctg ggctctgcaa ttccctctg | 9240 |
| ctgctgtccc tcccccttgc ccttccctt cagtaccctc tcagctccag gtggctctga | 9300 |
| ggtgccctgca ccacccccc ccccaagctca atggactgga aggggaaggg acacacaaga | 9360 |
| agaagggcac cctagttcta ctcaggcag ctcaagcagc gaccggcccc ttctctagct | 9420 |
| gtgggggtga gggTcccattg tggTggcaca ggcccccttgc agtggggta tctctgttt | 9480 |
| aggggtatat gatggggag tagatcttgc taggagggag acactggccc ctcaaattcg | 9540 |
| ccagcgacct tcctcatcca ccccatccct ccccagttca ttgacttttgc attagcagcg | 9600 |
| gaacaaggag tcagacattt taagatggtg gcagtagagg ctatggacag ggcacatccac | 9660 |
| gtgggctcat atggggctgg gagtagttgt ctTTTctggc actaacgttgc agcccccgg | 9720 |
| ggcactgaag tgcttagtgc acttggagta ttggggctgc accccaaaca cttccagct | 9780 |
| cctgtaacat actggcctgg actgtttctt ctcggctccc catgtgtctt ggTTcccgtt | 9840 |
| tctccaccta gactgtaaac ctctcgaggg cagggaccac accctgtact gttctgtgc | 9900 |

-continued

```

ttcacagct cctccccacaa tgctgaatat acaggcagggtg ctcaataaat gattcttagt 9960
gactttactt gtaatattac tattgtggtt attataccctt ataagaacaa ataaatgggc 10020
ttttggaaag gatttcataa ttaaaataatt taaaaaatta agcatttaaa tttagagaat 10080
gcagaaaaact tagcaaacag aaagactgct gcaaaaaaca acagcaaaac aaaaactact 10140
gtcacacctc tgcaaagatc accaatgtca atatttttgtt ttgttgtgtatcttttgt 10200
aaagaatata ttatagctt acatcattat tcatcagata aatgcaaatt aagataaccac 10260
aataagatac caccatacac ttaccagaat gattaaaaaa gactgacagt gccaaggcatt 10320
ggcaaggta tggagcaact ggatcttta tttaaaaaaa ctgtttgggc cggcgcaagt 10380
ggctcacacc tagaatccca gtgcattcggg aggctgaggc aggagatcac ttgaggccaa 10440
gggttcaaga ccagcctggc caacatggtg aaatctctac taaaaataca aaaattagct 10500
ggccatggtg gtgcacgctt gtaatcccag ctacttggaa ggctgagggtg ggaggatcac 10560
ttgaacccag gaggcagagg ttgcagtcag ctgagatcat accactgtac tccagcctct 10620
tccagggtga cagttagatt catctcaat aaatacataa ataaaaact gtttggtaat 10680
atcttctaaa gatgcctacc ttcatggcta cctcatgacc cagtaattctt attcctggac 10740
atgttctcga gagaaatgag ttcatatttc cactgaaaaa ggcataagaa tgttctacac 10800
agtggctcac acctataatc ccagcactt gggaggctaa ggcaggagga cggcttgagc 10860
ccaagagtgt gagaccagtt tggcaacat agcgagactc ttatctc 10907

```

<210> SEQ ID NO 17

<211> LENGTH: 164

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 17

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Met | Ser | Glu | Pro | Ala | Gly | Asp | Val | Arg | Gln | Asn | Pro | Cys | Gly | Ser | Lys |
| 1 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

5 10 15

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Cys | Arg | Arg | Leu | Phe | Gly | Pro | Val | Asp | Ser | Glu | Gln | Leu | Ser | Arg |
| 20 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

25 30

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Cys | Asp | Ala | Leu | Met | Ala | Gly | Cys | Ile | Gln | Glu | Ala | Arg | Glu | Arg |
| 35 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

40 45

| | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Asn | Phe | Asp | Phe | Val | Thr | Glu | Thr | Pro | Leu | Glu | Asp | Phe | Ala |
| 50 | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |

55 60

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Trp | Glu | Arg | Val | Arg | Gly | Leu | Gly | Leu | Pro | Lys | Leu | Tyr | Leu | Pro | Thr |
| 65 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

70 75 80

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Pro | Arg | Arg | Gly | Arg | Asp | Glu | Leu | Gly | Gly | Gly | Arg | Arg | Pro | Gly |
| 85 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

90 95

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Pro | Ala | Leu | Leu | Gln | Gly | Thr | Ala | Glu | Glu | Asp | His | Val | Asp |
| 100 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

105 110

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ser | Leu | Ser | Cys | Thr | Leu | Val | Pro | Arg | Ser | Gly | Glu | Gln | Ala | Glu |
| 115 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

120 125

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Ser | Pro | Gly | Gly | Pro | Gly | Asp | Ser | Gln | Gly | Arg | Lys | Arg | Arg | Gln |
| 130 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

135 140

| | | | | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Thr | Ser | Met | Thr | Asp | Phe | Tyr | His | Ser | Lys | Arg | Arg | Leu | Ile | Phe | Ser |
| 145 | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | |

150 155 160

Lys Arg Lys Pro

53

We claim:

1. A method for treating glaucoma, said method comprising topically administering to the eye of a patient in need thereof a therapeutically effective amount of a composition

54

comprising a Tanis antagonist, wherein said Tanis antagonist is α -lipoic acid and wherein the concentration of α -lipoic acid in said composition is from 0.01% to 5% by weight.

* * * * *